WO1996039815A1 - Psoralen-binding polymers - Google Patents
Psoralen-binding polymers Download PDFInfo
- Publication number
- WO1996039815A1 WO1996039815A1 PCT/US1996/007896 US9607896W WO9639815A1 WO 1996039815 A1 WO1996039815 A1 WO 1996039815A1 US 9607896 W US9607896 W US 9607896W WO 9639815 A1 WO9639815 A1 WO 9639815A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- psoralen
- platelet
- platelets
- solution
- plasma
- Prior art date
Links
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 title claims description 85
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 title claims description 41
- 229920000642 polymer Polymers 0.000 title claims description 11
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 210000004369 blood Anatomy 0.000 claims abstract description 39
- 239000008280 blood Substances 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims description 49
- 230000002186 photoactivation Effects 0.000 claims description 28
- 230000005670 electromagnetic radiation Effects 0.000 claims description 26
- 230000003213 activating effect Effects 0.000 claims description 20
- 244000005700 microbiome Species 0.000 claims description 14
- 230000000415 inactivating effect Effects 0.000 claims description 10
- 238000001228 spectrum Methods 0.000 claims description 10
- 230000036470 plasma concentration Effects 0.000 claims description 7
- 238000009472 formulation Methods 0.000 abstract description 18
- 238000001727 in vivo Methods 0.000 abstract description 7
- 210000001772 blood platelet Anatomy 0.000 description 114
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 47
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 46
- 229960004469 methoxsalen Drugs 0.000 description 46
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 45
- 210000002381 plasma Anatomy 0.000 description 43
- 238000003860 storage Methods 0.000 description 32
- 239000010836 blood and blood product Substances 0.000 description 30
- 229940125691 blood product Drugs 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 239000003634 thrombocyte concentrate Substances 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 230000005855 radiation Effects 0.000 description 19
- 102100023472 P-selectin Human genes 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 15
- 238000001994 activation Methods 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 230000002779 inactivation Effects 0.000 description 15
- 230000004913 activation Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 230000006378 damage Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 235000010355 mannitol Nutrition 0.000 description 12
- 229910019142 PO4 Inorganic materials 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 239000000306 component Substances 0.000 description 10
- 238000011109 contamination Methods 0.000 description 10
- 238000005202 decontamination Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000010452 phosphate Substances 0.000 description 10
- 241000894007 species Species 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 229930195725 Mannitol Natural products 0.000 description 9
- 239000000594 mannitol Substances 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000003588 decontaminative effect Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 230000005283 ground state Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 238000000429 assembly Methods 0.000 description 5
- 230000000712 assembly Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000012266 salt solution Substances 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012503 blood component Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000010118 platelet activation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 108010035766 P-Selectin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- -1 aromatic amino acids Chemical class 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 150000002211 flavins Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229940050410 gluconate Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical group O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 2
- 108020005075 5S Ribosomal RNA Proteins 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229910020630 Co Ni Inorganic materials 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229910002440 Co–Ni Inorganic materials 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 2
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960000850 trioxysalen Drugs 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- 229940027041 8-mop Drugs 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005321 cobalt glass Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000002352 nonmutagenic effect Effects 0.000 description 1
- 230000003546 nucleic acid damage Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940081858 plasmalyte a Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- UZKRBUWJQVLAOT-FFIPNUABSA-H tricalcium [(2R)-2-[(1S)-1,2-dihydroxyethyl]-3-oxido-5-oxo-2H-furan-4-yl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] UZKRBUWJQVLAOT-FFIPNUABSA-H 0.000 description 1
- PBSRSWFGYPZDAU-FFIPNUABSA-H trimagnesium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-oxido-5-oxo-2h-furan-4-yl] phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] PBSRSWFGYPZDAU-FFIPNUABSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0215—Disinfecting agents, e.g. antimicrobials for preserving living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0066—Psoralene-activated UV-A photochemotherapy (PUVA-therapy), e.g. for treatment of psoriasis or eczema, extracorporeal photopheresis with psoralens or fucocoumarins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/10—Ultra-violet radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3616—Batch-type treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
- A61M1/3686—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents by removing photoactive agents after irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
- A61M2202/0425—Thrombin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
- A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
Definitions
- the invention generally relates to synthetic media for use with blood preparations intended for in vivo use, including synthetic media used in conjunction with the photodecontamination of platelets.
- red blood cells whole blood collected from volunteer donors for transfusion recipients is typically separated into its components: red blood cells, platelets, and plasma. Each of these fractions are individually stored and used to treat a multiplicity of specific conditions and disease states.
- the red blood cell component is used to treat anemia
- the concentrated platelet component is used to control bleeding
- the plasma component is used frequently as a source of Clotting Factor VIII for the treatment of hemophilia.
- all blood cell preparations should be from freshly drawn blood and then immediately transfused to the recipient.
- the logistics of operating a blood donor center preclude this possibility in the vast majority of cases. Transfusions are needed day and night and it is difficult, if not impossible, to arrange for donor recruiting at unusual hours. Consequently, modern blood donor centers must use stored blood products.
- red blood cells can be stored up to forty-two days (depending upon the type of anticoagulant and storage medium used) and plasma may be frozen and stored for even longer periods. While red cells are stored in the cold, Murphy and Gardner, New Eng. J. Med. 280:1094 (1969).
- platelets stored as platelet-rich plasma (PRP) at 22°C possessed a better in vivo half-life than those stored at 4°C.
- PRP platelet-rich plasma
- more acceptable platelet concentrates could be transfused after storage at room temperature.
- the rules allowed for platelet concentrate storage at room temperature for up to seven days (depending upon the type of storage container).
- Platelet concentrates may now be stored for no more than five days.
- blood bags used for platelet concentrate preparation are in themselves sterile, as are the connected satellite bags.
- bacteria can be introduced by at least two different means.
- a second, more pervasive source of contamination is the venepuncture.
- venepuncture Even when "sterile" methods of skin preparation are employed, it is extremely difficult to sterilize the crypts around the sweat glands and hair follicles.
- this contaminated skin is often cut out in a small “core” by a sharp needle. This core can serve to "seed" the blood bag with bacteria that may grow and become a risk to the recipient.
- Holding platelet units for an additional two days to await the results of the assay would create, ironically, a smaller margin of safety. See Table 2 in J.F. Morrow et al, JAMA 266:555 (1991). While heavily contaminated units would be detected at the outset, lightly contaminated units would be allowed to grow for two days. Older and potentially more contaminated units would end up being transfused.
- washing the blood cells e.g., with saline
- filtering the bacteria are also not practical solutions. These techniques are time consuming and inefficient, as they can reduce the number of viable blood cells available for transfusion. Most importantly, they typically involve an "entry" into the storage system. Once an entry is made in a previously closed system, the system is considered “opened,” and transfusion must occur quickly, regardless of the manner in which the blood was collected and processed in the first place.
- antibiotics are not a reasonable solution. Contamination occurs from a wide spectrum of organisms. Antibiotics would be needed to cover this spectrum. Many recipients are allergic to antibiotics. In addition, there is an every increasing array of drug-resistant strains of bacteria that would not be inactivated.
- the invention generally relates to synthetic media for use with blood preparations intended for in vivo use, including synthetic media used in conjunction with the photodecontamination of platelets.
- synthetic media the present invention intends to indicate aqueous solutions (e.g., phosphate buffered, aqueous salt solutions) other than those found as natural fluids (e.g., plasma, serum, etc.).
- natural fluids e.g., plasma, serum, etc.
- the present invention contemplates a method of inactivating bacteria in platelet preparations for transfusions, comprising: a) providing, in any order, i) a phosphate buffered, aqueous salt solution comprising glucose and 8-methoxypsoralen; ii) means for activating 8-methoxypsoralen; and iii) a platelet preparation suspected of being contaminated with bacteria, comprising platelets and plasma; b) removing the plasma from the preparation and adding the solution to the platelets such that the platelets are suspended in a mixture having a residual plasma concentration between 8 and 25% by volume; and c) activating the 8-methoxypsoralen in the mixture with the activating means, so that the 8-methoxypsoralen inhibits the replication of the bacteria.
- the method further comprises the step, after step c), of storing said mixture at approximately room temperature prior to transfusion.
- the present invention contemplates sodium citrate, sodium acetate, and mannitol. However, it is preferred that the solutions contain no sodium gluconate and no bicarbonate.
- the activating means comprises a photoactivation device capable of emitting a given intensity of a spectrum of electromagnetic radiation comprising wavelengths between 180 nm and 400 nm, and in particular, between 320 nm and 380 nm. It is preferred that the intensity is less than 25 mW/cnr (e.g. between 10 and 20 mW/cnr) and that the mixture is exposed to this intensity for between one and twenty minutes (e.g. ten minutes).
- the present invention contemplates a method of inactivating bacteria in platelet preparations for transfusions, comprising: a) providing, in any order, i) a phosphate buffered, aqueous salt solution comprising approximately 2 mM glucose and 8-methoxypsoralen at a concentration between approximately 2 ug/ml and the maximum solubility of 8-methoxypsoralen in water; ii) means for activating the 8-methoxypsoralen; and iii) a platelet preparation suspected of being contaminated with bacteria, comprising platelets and plasma; b) removing the plasma from the preparation and adding the solution to said platelets such that said platelets are suspended in a mixture having a residual plasma concentration between 8 and 25% by volume; and c) activating the 8-methoxypsoralen in the mixture with the activating means, so that the 8-methoxypsoralen inhibits the replication of the bacteria.
- the present invention intends a concentration derived experimentally in an aqueous solution in the absence of organic solvents (e.g., DMSO, ethanol. etc.) at approximately room temperature. Concentrations exceeding this level are detected by the presence of precipitate, which is undesirable for intravenous infusion.
- organic solvents e.g., DMSO, ethanol. etc.
- a saturated solution of 8-methoxypsoralen can be made by simply dissolving the compound (over a number of hours at room temperature) in distilled water until precipitate is apparent. If the solution is simply centrifuged, the supernatant can have a concentration of over 50 ug ml. On the other hand, if the solution is filtered (e.g., glass wool), the concentration of 8-methoxypsoralen has been found to be under 50 ug/ml. If, instead of centrifuging or filtering, the saturated solution is dialyzed against distilled water (over a number of days at room temperature), the compound is found to have a maximum solubility of approximately 39 ug/ml.
- the present invention contemplates a method of inactivating bacteria in platelet preparations for transfusions, comprising: a) providing, in any order, i) an aqueous solution comprising glucose, sodium chloride, potassium chloride, magnesium chloride, monobasic and dibasic sodium phosphate, and 8-methoxypsoralen; ii) means for activating 8-methoxypsoralen; and iii) a platelet preparation suspected of being contaminated with bacteria, comprising platelets and plasma; b) removing the plasma from the preparation and adding the solution to the platelets such that the platelets are suspended in mixture having a residual plasma concentration between approximately 12 and 20% by volume; and c) activating the 8-methoxypsoralen in the mixture with the activating means, so that the 8-methoxypsoralen inhibits the replication of the bacteria.
- the present invention contemplates a synthetic platelet storage media, comprising an aqueous solution of: 45-100 mM sodium chloride: 4-5 mM potassium chloride; 10-15 mM sodium citrate; 20-27 mM sodium acetate; 2 mM glucose: 20-30 mM mannitol; 20 mM sodium phosphate; 2-3 mM magnesium chloride; and 8-methoxypsoralen.
- the present invention contemplates a method of inactivating microorganisms in platelet preparations for subsequent transfusion, comprising: a) providing, in any order; i) psoralen. ii) photoactivation means, and iii) a platelet preparation suspected of being contaminated with microorganisms, comprising platelets and plasma; b) adding said psoralen to said platelet preparation to create a solution of psoralen at a concentration; c) treating said solution with said photoactivation means so as to create a treated platelet preparation wherein said microorganisms are inactivated and wherein at least a portion of said psoralen concentration is free in said solution; and d) removing some of said free psoralen in said treated platelet preparation.
- removing some of said free psoralen refers to the removal of at least a portion of the psoralen free in solution.
- the method further comprises the step, after step d), of storing said mixture at approximately room temperature prior to transfusion.
- said activating means comprises a photoactivation device capable of emitting a given intensity of a spectrum of electromagnetic radiation comprising wavelengths between 320 nm and 380 nm; in certain embodiments, said intensity is less than 25 mW/cnr.
- said mixture is exposed to said intensity for between one and ten minutes.
- said removing of said free psoralen comprises contacting said platelets with a psoralen-binding polymer.
- said contacting comprises transferring said platelets to a blood bag comprised of psoralen-binding polymer.
- the present invention also contemplates a method of inactivating microorganisms in platelet preparation for transfusions, comprising: a) providing, in any order; i) psoralen, ii) synthetic media, iii) photoactivation means, and iv) a platelet preparation suspected of being contaminated with microorganisms, comprising platelets and plasma; b) removing a portion of said plasma from said preparation and adding said synthetic media containing said psoralen to said platelets such that said platelets are suspended in mixture having a residual plasma concentration; c) treating said mixture with said photoactivation means so as to create a treated platelet solution wherein said microorganisms are inactivated and wherein at least a portion of said psoralen concentration is free in said solution; and d) removing substantially all of said free psoralen in said treated platelet solution.
- the phrase "removing substantially all of said free psoralen” refers to removing at least approximately 90% of said free psoral
- the method further comprises the step, after step d), of storing said mixture at approximately room temperature prior to transfusion.
- said activating means comprises a photoactivation device capable of emitting a given intensity of a spectrum of electromagnetic radiation comprising wavelengths between 320 nm and 380 nm; in certain embodiments, said intensity is less than 25 mW/cnr.
- said mixture is exposed to said intensity for between one and ten minutes.
- said removing of said free psoralen comprises contacting said platelets with a psoralen-binding polymer.
- said contacting comprises transferring said platelets to a blood bag comprised of psoralen-binding polymer.
- FIGURES Figure 1 is a perspective view of one embodiment of the device of the present invention.
- Figure 2 is a cross-sectional view of the device shown in Figure 1 along the lines of
- Figure 3 is a cross-sectional view of the device shown in Figure 1 along the lines of
- Figure 4 is a cross-sectional view of the device shown in Figure 1 along the lines of
- Figure 5 schematically shows the decontamination approach of the present invention applied specifically to blood products.
- Figure 6 is a graph showing the photoaddition of 8-methoxypsoralen to nucleic acid.
- Figure 7 is a graph showing the degradation of 8-methoxypsoralen (8-MOP) compared to that of 4'-aminomethyl-4.5',8-trimethylpsoralen (AMT), as measured by HPLC.
- Figure 8 is a graph showing the inactivation of gram negative bacteria.
- Figure 9 is a graph showing pH results following treatment and platelet storage.
- Figure 10 is a graph showing aggregation results following treatment and platelet storage.
- Figure 1 1 is a graph showing ATP results following treatment and platelet storage.
- Figure 12A schematically shows the standard blood product separation approach used presently in blood banks.
- Figure 12B schematically shows an embodiment of the present invention whereby synthetic media is introduced to platelet concentrate prepared as in Figure 12A.
- Figure 12C schematically shows one embodiment of the decontamination approach of the present invention applied specifically to platelet concentrate diluted with synthetic media as in Figure 12B.
- the invention generally relates to synthetic media for use with blood preparations intended for in vivo use. including synthetic media used in conjunction with the photodecontamination of platelets.
- red blood cells As noted previously, whole blood is collected and typically separated into red blood cells, platelets, and plasma. Each of these fractions are individually stored under specific conditions prior to in vivo use. In many cases, the extent of contamination is related to the storage time because of growth. A process that inactivated microorganisms at the time of blood collection would be expected to prevent growth during storage.
- the present invention contemplates inactivating blood products after separation but before storage.
- a nucleic acid binding compound is selectively employed to treat contamination by microorganisms.
- the nucleic acid binding compound is selected from the group comprising furocoumarins.
- the furocoumarin is a psoralen that is activated by a photoactivation device.
- Psoralens are tricyclic compounds formed by the linear fusion of a furan ring with a coumarin. Psoralens can intercalate between the base pairs of double-stranded nucleic acids, forming covalent adducts to pyrimidine bases upon absorption of longwave ultraviolet light (UVA).
- UVA longwave ultraviolet light
- the inactivation method of the present invention provides a method of inactivating single cell and multicellular organisms, and in particular, bacteria, fungi, mycoplasma and protozoa.
- the method of the present invention does not cause harm to the blood product. There is no significant damage to cells and, therefore, no need to limit the concentration of molecular oxygen.
- the present invention contemplates using much lower concentrations of nucleic acid binding compounds than previously employed.
- the present invention contemplates using 8-MOP at concentrations of 30 ug/ml or less.
- a preferred concentration of 8-MOP for bacterial decontamination in platelet concentrates is 3 ug/ml or less. i.e.. a one hundred-fold lower concentration than employed by G.P. Wiesehahn et al., supra. Because lower concentrations are employed, solvents like DMSO (used to increase the solubility of 8-MOP) are unnecessary.
- the present invention contemplates using much lower doses of irradiation than previously described. This is accomplished with lower intensity irradiation sources, with wavelength cutoff filters (see below), and/or shorter irradiation times.
- the time of irradiation is variable and controlled from 1 second to 99 minutes, in one second increments.
- the device of the present invention is mounted on an agitator, giving horizontal unidirectional and sinusoidal motion of variable frequency and amplitude.
- heat from the lamps, ballasts and other sources is blocked from the bags.
- inactivation While it is not intended that the present invention be limited by the theory of inactivation. the use of lower compound concentrations and irradiation doses comes from and understanding that, where the present invention is applied to the decontamination of a single cell or multicellular organism (as opposed to a virus), a lower level of nucleic acid binding will achieve inactivation. In addition, it is recognized that it is not essential that inactivation be complete. That is to say, partial inactivation will be adequate as long as the viable portion is unable, within the storage period, to grow to levels sufficient to cause disease. To appreciate that, in any given case, an inactivation method may or may not achieve complete inactivation, it is useful to consider a specific example.
- a bacterial culture is said to be sterilized if an aliquot of the culture, when transferred to a fresh culture plate and permitted to grow, is undetectable after a certain time period.
- the time period and the growth conditions define an "amplification factor".
- This amplification factor along with the limitations of the detection method (e.g., visual inspection of the culture plate for the appearance of a bacterial colony) define the sensitivity of the inactivation method.
- a minimal number of viable bacteria must be applied to the plate for a signal to be detectable. With the optimum detection method, this minimal number is 1 bacterial cell. With a suboptimal detection method, the minimal number of bacterial cells applied so that a signal is observed may be much greater than 1.
- the detection method determines a "threshold" below which the method appears to be completely effective (and above which the method is. in fact, only partially effective).
- bacterial cells can be applied to a plate; the detection method is arbitrarily chosen to be visual inspection. Assume the growth conditions and time are such that an overall amplification of 10 4 has occurred. The detectable signal will be proportional to the number of bacterial cells actually present after amplification. For calculation purposes, the detection threshold is taken to be 10 6 cells; if fewer than 10 6 cells are present after amplification, no cell colonies are visually detectable and the inactivation method will appear effective. Given the amplification factor of 10 4 and a detection threshold of 10 6 .
- the sensitivity limit would be 100 bacterial cells; if less than 100 viable bacterial cells were present in the original aliquot of the bacterial culture after the sterilization method is performed, the culture would still appear to be sterilized. Such a situation is common for bacterial growth assays.
- the sensitivity of the assay is such that viable bacterial cells are present but the assay is unable to detect them. This may explain, at least in part, the variability in results obtained by researchers attempting to determine the extent of bacterial contamination of blood products. See D.H. Buchholz, et al. Transfusion 13:268 (1973), wherein such variability is discussed. It should be noted that, in many countries, contamination of blood products by cellular organisms is more pervasive and, therefore, more serious than viral contamination.
- T. cruzi. which is the etiologic agent of Chagas disease. Approximately 16-18 million people are infected in the Americas (including 11% of the population of Chile). It is contemplated that the decontamination method of the present invention is well-suited for inactivation of this protozoa.
- the present invention contemplates specific synthetic media formulations for use with blood preparations.
- the formulations of the present invention are particularly useful for platelet storage. These formulations are also useful when employed in conjunction with the photodecontamination of platelets.
- U.S. Patent No. 4,447,415 to Rock describes a synthetic medium consisting essentially of: a balanced, physiologically compatible, saline solution: an anticoagulant; and one or more additives to enhance stability of the platelets selected from: (a) nutrients to improve the storage life of the platelets; (b) reversible inhibitors for platelet activation: (c) substances to raise cyclic adenosine monophosphate levels which have reversible effects on platelets; and
- 4.390,619 to Harmening-Pittiglio discloses a media capable of supporting platelet metabolism, containing a water-insoluble polymer containing releasable phosphate or bicarbonate ions.
- the formulations of the present invention i) contain glucose; ii) utilize residual plasma; and iii) avoid bicarbonate. It has been found that glucose is indeed beneficial as an element in the synthetic media.
- the present invention contemplates that a standard plasma expression method (e.g., such as currently used in most blood banks) will be used, such that platelets are suspended in a residual plasma concentration between 8 and 25% by volume, and more commonly 12 to 20%.
- Bicarbonate has been found to be extremely difficult to control in a system employing gas permeable blood bags.
- the present invention therefore contemplates a phosphate buffer to control the pH of the blood preparation.
- the present invention contemplates devices and methods for photoactivation and specifically, for activation of photoreactive nucleic acid binding compounds.
- the present invention contemplates devices having an inexpensive source of electromagnetic radiation that is integrated into a unit.
- the present invention contemplates a photoactivation device for treating photoreactive compounds, comprising: a) means for providing appropriate wavelengths of electromagnetic radiation to cause activation of at least one photoreactive compound: b) means for supporting a plurality of blood products in a fixed relationship with the radiation providing means during activation: and c) means for maintaining the temperature of the blood products within a desired temperature range during activation.
- the present invention also contemplates methods, comprising: a) supporting a plurality of blood product containers, containing one or more photoreactive compounds, in a fixed relationship with a fluorescent source of electromagnetic radiation; b) irradiating the plurality of blood products simultaneously with said electromagnetic radiation to cause activation of at least one photoreactive compound; and c) maintaining the temperature of the blood products within a desired temperature range during activation.
- the major features of one embodiment of the device of the present invention involve: A) an inexpensive source of ultraviolet radiation in a fixed relationship with the means for supporting the sample vessels; B) rapid photoactivation; C) large sample processing; D) temperature control of the irradiated samples; and E) inherent safety.
- a preferred photoactivation device of the present invention has an inexpensive source of ultraviolet radiation in a fixed relationship with the means for supporting the sample vessels.
- Ultraviolet radiation is a form of energy that occupies a portion of the electromagnetic radiation spectrum (the electromagnetic radiation spectrum ranges from cosmic rays to radio waves).
- Ultraviolet radiation can come from many natural and artificial sources. Depending on the source of ultraviolet radiation, it may be accompanied by other (non-ultraviolet) types of electromagnetic radiation (e.g., visible light).
- Particular types of ultraviolet radiation are herein described in terms of wavelength. Wavelength is herein described in terms of nanometers ("nm"; 10 "9 meters). For purposes herein, ultraviolet radiation extends from approximately 180 nm to 400 nm.
- a radiation source when a radiation source, by virtue of filters or other means, does not allow radiation below a particular wavelength (e.g., 320 nm), it is said to have a low end “cutoff at that wavelength (e.g., "a wavelength cutoff at 300 nanometers”). Similarly, when a radiation source allows only radiation below a particular wavelength (e.g., 360 nm), it is said to have a high end “cutoff at that wavelength (e.g., "a wavelength cutoff at 360 nanometers”).
- any photochemical reaction it is desired to eliminate or least minimize any deleterious side reactions.
- Some of these side reactions can be caused by the excitation of endogenous chromophores that may be present during the photochemical activation procedure.
- the endogenous chromophores are the nucleic acid bases themselves. Restricting the activation process to wavelengths greater than 320 nm minimizes direct nucleic acid damage since there is very little absorption by nucleic acids above 313 nm.
- the nucleic acid is typically present together with additional biological chromophores. If the biological fluid is just protein, the 320 nm cutoff will be adequate for minimizing side reactions (aromatic amino acids do not absorb above 320 nm). If the biological fluid includes cells and/or cellular constituents, there will be many other chromophores, including hemes and flavins.
- Hemes are abundant in blood products where they arise from the lysis of red cells. Flavins, like hemes. are required for metabolic respiration. Both of these endogenous chromophores will cause damage to cells if excited by photoirradiation.
- Hemes have three principle absorption bands: two are in the red region of the visible spectrum; the other is centered about 400 nm. Flavins have two principle absorption peaks: one at 450 nm and the other at 370 nm.
- the device of the present invention be designed to allow for irradiation within a small range of specific and desirable wavelengths, and thus avoid damage to cells caused by energy transfer.
- the preferred range of desirable wavelengths is between 320 and 350 nm.
- Some selectivity can be achieved by choice of commercial irradiation sources. For example, while typical fluorescent tubes emit wavelengths ranging from 300 nm to above 400 nm (with a broad peak centered around 360 nm), BLB type fluorescent lamps are designed to remove wavelengths above 400 nm. This, however, only provides an upper end cutoff.
- the device of the present invention comprises an additional filtering means.
- the filtering means comprises a glass cut-off filter, such as a piece of Cobalt glass.
- the filtering means comprises a liquid filter solution that transmit only a specific region of the electromagnetic spectrum, such as an aqueous solution of Co(No 3 ) 2 . This salt solution yields a transmission window of 320-400 nm.
- the aqueous solution of Co(No 3 ) 2 is used in combination with NiSO 4 to remove the 365 nm component of the emission spectrum of the fluorescent or arc source employed.
- the Co-Ni solution preserves its initial transmission remarkably well even after tens of hours of exposure to the direct light of high energy sources.
- cupric sulfate is a most useful general filter for removing the infra-red, when only the ultraviolet is to be isolated. Its stability in intense sources is quite good.
- Other salts are known to one skilled in the art.
- Aperture or reflector lamps may also be used to achieve specific wavelengths and intensities.
- UV radiation is herein described in terms of irradiance. it is expressed in terms of intensity flux (milliwatts per square centimeter or “mW cm '2" ).
- Output is herein defined to encompass both the emission of radiation (yes or no; on or off) as well as the level of irradiance. In a preferred embodiment, intensity is monitored at 4 locations: 2 for each side of the plane of irradiation.
- a preferred source of ultraviolet radiation is a fluorescent source.
- Fluorescence is a special case of luminescence. Luminescence involves the absorption of electromagnetic radiation by a substance and the conversion of the energy into radiation of a different wavelength. With fluorescence, the substance that is excited by the electromagnetic radiation returns to its ground state by emitting a quantum of electromagnetic radiation. While fluorescent sources have heretofore been thought to be of too low intensity to be useful for photoactivation. in one embodiment the present invention employs fluorescent sources to achieve results thus far achievable on only expensive equipment.
- fixed relationship is defined as comprising a fixed distance and geometry between the sample and the light source during the sample irradiation.
- Distance relates to the distance between the source and the sample as it is supported. It is known that light intensity from a point source is inversely related to the square of the distance from the point source. Thus, small changes in the distance from the source can have a drastic impact on intensity. Since changes in intensity can impact photoactivation results, changes in distance are avoided in the devices of the present invention. This provides reproducibility and repeatability.
- Geometry relates to the positioning of the light source. For example, it can be imagined that light sources could be placed around the sample holder in many ways (on the sides, on the bottom, in a circle, etc.).
- the geometry used in a preferred embodiment of the present invention allows for uniform light exposure of appropriate intensity for rapid photoactivation.
- the geometry of a preferred device of the present invention involves multiple sources of linear lamps as opposed to single point sources. In addition, there are several reflective surfaces and several absorptive surfaces. Because of this complicated geometry, changes in the location or number of the lamps relative to the position of the samples to be irradiated are to be avoided in that such changes will result in intensity changes.
- the light source of the preferred embodiment of the present invention allows for rapid photoactivation.
- the intensity characteristics of the irradiation device have been selected to be convenient with the anticipation that many sets of multiple samples may need to be processed. With this anticipation, a fifteen minute exposure time or less is a practical goal.
- relative position of the elements of the preferred device have been optimized to allow for fifteen minutes of irradiation time, so that, when measured for the wavelengths between 320 and 350 nanometers, an intensity flux greater than approximately 1 mW cm '2 is provided to the sample vessels.
- the device irradiates both sides of the bag.
- one element of the devices of the present invention is a means for supporting a plurality of blood products, and in particular, blood bags.
- the supporting means comprises glass plates between two banks of lights with a capacity of six 50 ml bags (equivalent to Dupont Stericell bag) plus connectors and tubing, at one time.
- Temperature control is important because the temperature of the sample in the sample at the time of exposure to light can dramatically impact the results. For example, conditions that promote secondary structure in nucleic acids also enhance the affinity constants of many psoralen derivatives for nucleic acids. Hyde and Hearst, Biochemistry, 17, 1251 (1978). These conditions are a mix of both solvent composition and temperature. With single stranded 5S ribosomal RNA, irradiation at low temperatures enhances the covalent addition of HMT to 5S rRNA by two fold at 4°C compared to 20°C. Thompson et al. J. Mol. Biol. 147:417 (1981). Even further temperature induced enhancements of psoralen binding have been reported with synthetic polynucleotides. Thompson et al. Biochemistry 21 :1363 (1982).
- Ultraviolet radiation can cause severe burns. Depending on the nature of the exposure, it may also be carcinogenic.
- the light source of a preferred embodiment of the present invention is shielded from the user. This is in contrast to the commercial hand-held ultraviolet sources as well as the large, high intensity sources.
- the irradiation source is contained within a housing made of material that obstructs the transmission of radiant energy (i.e., an opaque housing). No irradiation is allowed to pass to the user. This allows for inherent safety for the user. EXPERIMENTAL
- phosphate buffered synthetic media is formulated for platelet storage and treatment. In some cases, it may be convenient to make up the formulation in two steps. For example, in the preparation of S 2.22, a monobasic phosphate solution can be prepared as the first step:
- Distilled water is added to make 1 liter, the solution is mixed, sterile filtered (0.2 micron filter) and refrigerated. At the same time, a dibasic phosphate solution is prepared as a second step:
- distilled water is added to make 1 liter, the solution is mixed, sterile filtered (0.2 micron filter) and refrigerated.
- the monobasic solution is added to the dibasic solution to a pH of 7.4.
- the media can be made in one step.
- S. 4.0 can be made in one step, resulting in a pH balanced solution (e.g., pH 7.2), by combining the following reagents in 2 liters of distilled water:
- the solution is mixed, sterile filtered (0.2 micron filter) and refrigerated.
- a photoactivation device for decontaminating blood products according to the method of the present invention.
- This device comprises: a) means for providing appropriate wavelengths of electromagnetic radiation to cause activation of at least one photoreactive compound: b) means for supporting a plurality of blood products in a fixed relationship with the radiation providing means during activation; and c) means for maintaining the temperature of the blood products within a desired temperature range during activation.
- Figure 1 is a perspective view of one embodiment of the device integrating the above-named features.
- the figure shows an opaque housing (100) with a portion of it removed, containing an array of bulbs (101) above and below a plurality of representative blood product containing means (102) placed between plate assemblies (103. 104).
- the plate assemblies (103, 104) are described more fully, subsequently.
- the housing (101) can be opened via a latch (105) so that the blood product can be placed appropriately.
- the housing (100) when closed, completely contains the irradiation from the bulbs (101).
- the user can confirm that the device is operating by looking through a safety viewport (106) which does not allow transmission of ultraviolet light to the user.
- the housing (100) also serves as a mount for several electronic components on a control board (107), including, by way of example, a main power switch, a count down timer, and an hour meter.
- a main power switch can be wired to the count down timer which in turn is wired in parallel to an hour meter and to the source of the electromagnetic radiation.
- the count down timer permits a user to preset the irradiation time to a desired level of exposure.
- the hour meter maintains a record of the total number of radiation hours that are provided by the source of electromagnetic radiation. This feature permits the bulbs
- Figure 2 is a cross-sectional view of the device shown in Figure 1 along the lines of
- FIG. 2 shows the arrangement of the bulbs (101) with the housing (100) opened.
- a reflector (108A. 108B) completely surrounds each array of bulbs ( 101).
- Blood product containing means (102) are placed between upper (103) and lower ( 104) plate assemblies.
- Each plate assembly is comprised of an upper (103 A, 104A) and lower (103B, 104B) plates.
- the plate assemblies (103, 104) are connected via a hinge (109) which is designed to accommodate the space created by the blood product containing means (102).
- the upper plate assembly (103) is brought to rest gently on top of the blood product containing means
- Detectors (1 10A, HOB, HOC. HOD) may be conveniently placed between the plates (103A. 103B, 104A, 104B) of the plate assemblies (103, 104). They can be wired to a printed circuit board (111) which in turn is wired to the control board (107).
- Figure 3 is a cross-sectional view of the device shown in Figure 1 along the lines of 3—3.
- Six blood product containing means (102) e.g., TeflonTM platelet unit bags
- the temperature of the blood product can be controlled via a fan (112) alone or, more preferably, by employing a heat exchanger (113) having cooling inlet (114) and outlet (115) ports connected to a cooling source (not shown).
- Figure 4 is a cross-sectional view of the device shown in Figure 1 along the lines of 4—4. Figure 4 more clearly shows the temperature control approach of a preferred embodiment of the device.
- the fan (112) can circulate air within and between the chambers (103C. 104C).
- the heat exchanger (113) is employed, the circulating air is cooled and passed between the plates (103 A. 103B, 104A, 104B).
- FIG 5 shows an embodiment wherein platelets are treated by the method of the present invention.
- platelets are transferred to a bag containing a nucleic acid binding compound (shown in Figure 5 as a shaded bag).
- This bag which has transmission properties and other characteristics suited for the present invention. is then placed in an irradiation device (such as that described in Example 1. above) and is irradiated.
- the free compound may be collected or "captured" as desired by a capture device.
- the bag would contain only compound that is contained in cells; the bag would have no free compound (this bag is indicated in Figure 5 as unshaded).
- a bag comprised of a psoralen-binding polymer is employed to capture the compound.
- the Cutter CLX bag has been found to have this property.
- EXAMPLE 3 the decontamination methods of the present invention are applied to inactivate Klebsiella pneumoniae, which is known to be among the organisms associated with bacteremia. See generally, Infect. Control 5:343 (1984). The particular isolate in this case was obtained following a platelet transfusion where the recipient immediately went into shock and later died. The platelet bag was obtained and cultured, and the organism was identified and sero typed.
- the strain was kept at ambient temperature and inoculated onto either heart infusion agar (HIA) or heart infusion agar containing 5% (v/v) sheep blood (BAP) by swabbing each plate for confluency via a sterile applicator swab. Cultures were then incubated under static conditions for 16 - 18h at 35°C. At the end of the incubation period, cultures were removed and suspended in phosphate buffered saline (PBS;pH 7.2-7.4) and spectrophotometrically standardized to 1.0 at an OD 610 using a Spectronic 501 or 601 spectrophotometer (Bausch and Lomb).
- HOA heart infusion agar
- BAP heart infusion agar containing 5% (v/v) sheep blood
- suspensions were diluted 1 :10 in PBS to achieve an ca. 10 8 CFU/ml concentration. This standardized suspension is then split to use an aliquot for the inactivation study, while another portion was plated in duplicate 10-fold serial dilutions onto HIA (or BAP) to ensure appropriate concentrations of the organism.
- F24T 12-BL-HO fluorescent lamps were used. These are high output "black light” tubes (engineered to emit specific wavelengths by means of an internal phosphor coating) 24 inches in length. Total intensity is less than 25 mw/cnr and typically between 15 and 20 mw/c ⁇ r.
- bacteria were quantified by plating 0.1 ml of serial 10-fold dilutions in broth onto 100 mm petri dishes containing BHI agar. After 24 hr incubation at 35°C. colonies were counted and bacterial concentration was calculated on a per ml basis.
- EXAMPLE 4 Artuc and co-workers examined the solubility of 8-MOP in human and bovine serum proteins. They showed that, when working with 8-MOP concentrations ranging from 100 to 1000 ng/ml in serum. 75% to 80% of the 8-MOP was bound to albumin. M. Artuc et al, Brit. J. Derm. 101 :669 (1979).
- the binding of 8-MOP to Calf Thymus DNA is compared using plasma and a protein free media in order to validate the efficiency of psoralen-nucleic interactions under the decontamination methods of the present invention.
- this measurement used eukaryotic nucleic acid rather than bacterial nucleic acid, it is a useful indicator of the degree of adduct formation for bacteria.
- ⁇ -8-MOP was prepared to a concentration of 115 ug/ml in ethanol at a specific activity of 4.7 x 10 6 CPM/microgram (hereinafter "8-MOP stock"). Thereafter 130.5 or 22 ul of 8-MOP stock (2 each) for samples containing DNA ("+ DNA”) and 52.2 or 8.7 ul for samples not containing DNA ("- DNA”) were dried down. To + DNA samples. 40 ul of DNA stock (7.7 mg/ml) was added as well as either 460 ul plasma (day old frozen) or 450 ul Tris-EDTA ("TE”) buffer. To the latter was also added 10 ul 5M NaCl. For - DNA samples (i.e., the controls), 184 ul plasma and 16 ul water was added.
- the samples were mildly vortexed for approximately one hour and the counts were checked to confirm that the 8-MOP dissolved.
- Each sample (100 ul) was irradiated on an HRI-100 (HRI Research Inc.. Concord. CA) at 25 °C for 0. 2. 4, 8, and 16 minutes. Samples were kept at 4°C overnight after irradiation. Thereafter, the samples were extracted. First, a phenol solution was prepared at pH 8 by equilibrating with 0.1 M Tris pH 8. Each sample was then extracted with 100 ul phenol. Each sample was centrifuged for 5 minutes to remove the aqueous phase to a new tube. A second extraction was performed with 100 ul 1 :1 phenolxhloroform. A final extraction was performed with 100 ul chloroform.
- the final aqueous phase was precipitated by adding 50 ul NaCl adjusted to give a final concentration of NaCl of 0.2 M and then adding 250 ul ethanol. The samples were again centrifuged (10 minutes). The supernatant was removed and the pellets were dried. The pellets were resuspended in 100 ul TE and reprecipitated. This was repeated for a total of 3 precipitations. The final pellets were brought up in 600 ul water and 100 ul was counted. Each sample was assayed for DNA by measuring absorbance (260 nm). 8-MOP levels were plotted as adducts per 1000 base pairs ("8-MOP:kBP").
- the frequency of 8-MOP-DNA adduct formation in protein free media predicts a high multiplicity of modification of the bacterial genome. Furthermore, this type of biochemical measurement has the potential to provide a means to monitor the efficiency of the photochemical inactivation method.
- Photoactivation of psoralens and isopsoralens may result in a variety of photoproducts.
- Photoproduct is best understood by considering the possible reactions of photoreactive compound when exposed to activating wavelengths of electromagnetic radiation. While not limited to any precise mechanism, it is believed that the reaction of photoreactive compound in its ground state (“C") with activating wavelengths of electromagnetic radiation creates a short-lived excited species (“C*”):
- the excited species may react with itself (i.e.. a ground state or excited species) to create a ground state complex ("C:C").
- C:C ground state complex
- the product of these self-reactions where two compounds react is referred to as "photodimer” or simply “dimer.”
- the self-reactions are not limited to two compounds; a variety of multrimers may be formed (trimers, etc.).
- the excited species is not limited to reacting with itself. It may react with its environment, such as elements of the solvent ("E”) (e.g., ions, gases, etc.) to produce other products:
- E elements of the solvent
- excited species may undergo other reactions than described here.
- Photoproduct does not depend on which one (if any) of these reactions actually occurs.
- Photoproduct - whatever its nature - is deemed to exist if, following the reaction of a compound and activating wavelengths of electromagnetic radiation, there is a resultant product formed that can interact with other components of the reaction environment.
- HMT 4'-hydroxymethyl-4,5'.8-trimethylpsoralen
- the major resultant products of HMT are two cyclobutyl photodimers.
- the two pyrone rings are linked in a cis-syn configuration, while in the other dimer. the linkage occurs between the furan end of one molecule and the pyrone end of the other, again with cis-syn configuration.
- a third resultant product of HMT is a monomeric HMT photoisomer. In this isomer. the central ring oxygens assume a 1, 4 instead of the normal 1. 3 orientation.
- the photoisomer While the two photodimers would not be expected to have an intercalating activity due to geometrical considerations, the photoisomer remains planer, and accordingly, it is contemplated that it has a positive intercalative association with double stranded nucleic acid and. thus, could be a mutagen.
- the samples were analyzed by reverse phase HPLC using a Rainen Dynamax 300A column.
- Standard solutions of each compound were prepared at various concentrations. These solutions were then diluted 1 : 10 into water, then 300 ul injected for analysis. All samples were monitored at 300 nm. Peaks were analyzed by measuring either peak height or peak area, then converted to a gh ml value using the standard plot. Peak area was determining by photocopying the trace, cutting out the copy of the peak, then weighing the resultant trace.
- GMP140 alpha granule membrane glycoprotein
- GMP140 GMP140-binding antibody or control mouse IgG.
- CD62 is a commercially available monoclonal antibody which binds to GMP140 (available from Sanbio. Uden. the Netherlands: Caltag Labs. So. San Francisco. CA. and Becton Dickinson. Mountain View, CA).
- Goat Anti-Mouse IgG conjugated to FITC is added to the tube in saturating amounts and allowed to incubate at room temperature (RT) for 15 minutes.
- RT room temperature
- the cells are diluted in isotonic saline, fixed with paraformaldehyde and analyzed on a FACSCAN (Becton Dickinson. Mountain View,
- the positive control is made by adding Phorbol Myristate Acetate (PMA) to the test system at a final concentration of 10- 7 M.
- PMA Phorbol Myristate Acetate
- CD62 was employed to measure the impact, if any, of irradiation alone on platelet activation.
- the antibody was stored in small aliquots (0.01 mg/ml) at -20°C prior to use.
- a mouse IgG control (0.05 mg/ml) (Becton Dickinson, Mountain View. CA #9040) 5X concentrated was employed. At time of use, this was diluted 1 :5 in HEPES buffer.
- the secondary antibody was goat Anti-Mouse IgG conjugated to FITC (TAGO, Burlingame, CA #3506). This was stored in small aliquots at -20°C.
- Phorbol Myristate Acetate (PMA) (Sigma. St. Louis, MO) was stored at -20°C. At time of use, this was dissolved in DMSO (working concentration was 1.62 X 10- 5 M).
- Paraformaldehyde (Sigma, St. Louis. MO) was prepared by adding 16 grams paraformaldehyde to 100 ml deionized water. This was heated to 70°C, whereupon 3 M NaOH was added dropwise until the solution was clear. The solution was cooled and the pH was adjusted to 7.4 with 1 N HCl. This was filtered and stored. A commercially available isotonic buffer was used: Hematall Isotonic Diluent (Fisher # CS 606-20).
- a unit of human platelets was obtained from the Blood Bank of Alameda-Contra Costa Medical Association. 5 ml aliquots were drawn from the bag and received specified amounts of UVA irradiation, except for the control, which received no treatment other than being placed in a chamber for irradiation. Temperature was maintained at 25°C during irradiation by placing platelet concentrate in stoppered siliconized glass water-jacketed chambers attached to a circulating water bath. The irradiation device (Derma Control, Dolton, 111.; Model No. 1224-Special) was as described in Example 3. above.
- the platelets were stored for 5 days. At specific time points, aliquots were taken and processed.
- Processing involved adding an aliquot (e.g., 5 microliters) of platelet concentrate to each microcentrifuge tube containing the antibody CD62, and appropriate reagents and this was mixed very gently by vortex. The samples were incubated for 15 minutes at room temperature.
- an aliquot e.g., 5 microliters
- Goat anti-Mouse IgG-FITC (diluted 1 :10 in HEPES buffer) was added (5 microliters) to each tube and the solution was mixed by gentle vortex. The samples were incubated for an additional 15 minutes at room temperature.
- Isoton II was added (1 ml) to each tube and mixed gently with a polypropylene disposable pipet. 8% PFA in HEPES (150 microliters) was added to each diluted sample to final 1%). The platelets were analyzed on the FACSCAN. The results are shown in Table 1.
- Activation is expressed as a percent. Clearly, irradiation for ten minutes (UV 10') resulted in a significant negative impact on stored platelets; the platelets were highly activated. By contrast, irradiation for five minutes (UV 5') resulted in no significant activation above the control which received no irradiation.
- Example 6 Given the results of Example 6, it is clear that either a shorter irradiation time or the use of filters is needed to avoid damage to cells by UV irradiation.
- CD62 is employed to measure the impact of irradiation in the presence of psoralen on platelet activation. Shorter irradiation times and wavelength filters are separately employed.
- Example 3 above. Following irradiation, the platelets are again stored for 5 days as in Example 6. At specific time points, aliquots are taken and assayed with the CD62 antibody and analyzed on the FACSCAN to show that, under these conditions, platelets can be decontaminated without damage to the cells and stored for five days prior to transfusion.
- Wavelength Filters An aqueous solution of Co(No 3 ) 2 is used in combination with NiSO 4 to substantially remove the 365 nm component of the emission spectrum of the light source employed.
- the Co-Ni solution can be conveniently used in place of water as a coolant during the irradiation.
- the platelets are stored and assayed with the CD62 antibody on the FACSCAN to show that, under these conditions, platelets can be decontaminated without damage to the cells and stored for five days prior to transfusion.
- This example involves an assessment of the impact of mannitol on platelet function in synthetic media following irradiation.
- Three indicators of platelet viability and function were employed: 1) maintenance of pH; 2) platelet aggregation; and 3) ATP release.
- a commercial device was used to measure pH.
- a small amount of platelet concentrate was introduced into a CIBA-CORNING 238 pH/Blood Gas analyzer. Platelet aggregation and ATP release were measured with a CHRONOLOG Platelet Aggregometer with a Luminescence channel. The number of platelets in samples was controlled to be constant for every measurement.
- a Sysmex cell counter was used to measure platelet count in the platelet samples and AB plasma was used to adjust platelet counts to 300.000 per microliter of platelet concentrate.
- the optical channel is used for platelet aggregation measurement.
- a proportional amount of platelet concentrate and AB plasma were centrifuged at high speed (14,000 g) with a microfuge for 5 minutes in order to obtain platelet poor plasma.
- the aggregometer was warmed up to 37°C.
- the magnetic speed of the aggregometer was set at 600 /min and the Gain setting was set for the luminescence channel at 0.02.
- 0.45 ml of platelet poor plasma was added along with 0.5 ml of saline into a glass cuvette and placed in the PPP channel.
- ATP standard was prepared in saline in four 10 ul aliquots (0.5, 1.0. 1.5 and 2.0 nmoles of ATP).
- 0.45 ml of platelet concentrate and 0.5 ml of saline were added to a cuvette (containing a small magnet) into the sample channel. After one minute. 30 ul of Lume enzyme was added. After one minute. 10 ul of ATP standard was added. With the standard curve, the amount of ATP released from each sample was then determined.
- a fresh unit of human platelet concentrate was obtained from Alameda-Contra Costa Blood Bank. As a control.
- the units were allowed to rest for one hour without shaking or mixing. Following a gentle kneading of the platelet pellet to resuspend the platelets, the bag was placed back on the rotator. The volume of platelet concentrate in the plasmalyte was measured to equal 42 ml (30 ml plasmalyte and 12 ml of plasma). 38 ml plasmalyte was added to the platelet suspension to give a 15% final plasma solution.
- FIG. 9 is a graph showing pH results.
- Figure 10 is a graph showing aggregation results, and
- Figure 11 is a graph showing ATP results.
- Figure 9. 10, and 11 indicate that extensive damage were obtained by one minute UVA irradiation on platelets resuspended in plasmalyte stored for 4 days. However, 2 and 10 mM mannitol protected platelets during a 2.5 minute UVA irradiation. Clearly, mannitol is helpful in synthetic media to preserve platelet function following irradiation.
- EXAMPLE 9 This example involves an assessment of new synthetic media formulations as measured by the following in vitro platelet function assays: 1) maintenance of pH; 2) platelet aggregation ("Agg"); 3) ATP release; and 4) GMP140 expression. The assays for each of these tests have been described above.
- the unit was centrifuged at room temperature for 6 minutes at 4000 rpm and then transferred to a unit press. Using an attached transfer line, plasma was expressed from the unit, leaving approximately 9.4 mis of residual plasma.
- the unit was allowed to rest for 1 hour, after which it was gently kneaded to resuspend the platelets.
- the reconstituted unit was assayed for pH and other tests the next day. with the following results:
- Figure 12 shows an embodiment wherein platelets are diluted with synthetic media by the method of the present invention.
- Figure 12A schematically shows the standard blood product separation approach used presently in blood banks.
- Three bags are integrated by flexible tubing to create a blood transfer set (200) (e.g., commercially available from Baxter, Deerfield, 111.).
- a blood transfer set 200
- the entire set is processed by centrifugation (e.g., SorvallTM swing bucket centrifuge, Dupont), resulting in packed red cells and platelet rich plasma in the first bag (201).
- the plasma is expressed off of the first bag (201) (e.g., using a FenwallTM device for plasma expression), through the tubing and into the second bag (202).
- the first bag (201) is then detached and the two bag set is centrifuged to create platelet concentrate and platelet-poor plasma; the latter is expressed off of the second bag (202) into the third bag (203).
- FIG 12B schematically shows an embodiment of the present invention by which synthetic media is introduced to platelet concentrate prepared as in Figure 12A.
- a two bag set (300) is sterile docked with the platelet concentrate bag (202) (indicated as "P.C.”).
- P.C platelet concentrate bag
- Sterile docking is well-known to the art. See e.g., U.S. Patent No. 4,412,835 to D.W.C. Spencer, hereby incorporated by reference. See also U.S. Patents Nos. 4,157,723 and 4.265.280. hereby incorporated by reference. Sterile docking devices are commercially available (e.g., Terumo. Japan).
- One of the bags (301) of the two bag set (300) contains a synthetic media formulation of the present invention (indicated as "STERILYTE").
- the platelet concentrate is mixed with the synthetic media by transferring the platelet concentrate to the synthetic media bag (301).
- Figure 12C schematically shows one embodiment of the decontamination approach of the present invention applied specifically to platelet concentrate diluted with synthetic media as in Figure 12B.
- platelets have been transferred to a synthetic media bag (301) containing a nucleic acid binding compound.
- This bag (301) which has UV light transmission properties and other characteristics suited for the present invention, is then placed in a device (such as that described in Example 1 , above) and illuminated.
- the storage bag can be a commercially available storage bag (e.g., CLX bag from Cutter).
- the present invention provides synthetic media formulations for use with blood preparations intended for storage and in vivo use.
- the formulations include synthetic media formulations to be employed in conjunction with the photodecontamination of platelets.
Abstract
Synthetic media formulations are disclosed for use with blood preparations intended for in vivo use, including synthetic media formulations to be employed in conjunction with the photodecontamination of platelets.
Description
PSORALEN-BINDING POLYMERS
The present application is a continuation application of application Serial No. 08/072,485 filed June 2, 1993. which is a continuation-in-part of application Serial No. 07/926.477 filed August 7, 1992. which is a continuation-in-part of application Serial No. 07/844.790 filed March 2, 1992.
FIELD OF THE INVENTION
The invention generally relates to synthetic media for use with blood preparations intended for in vivo use, including synthetic media used in conjunction with the photodecontamination of platelets.
BACKGROUND
Whole blood collected from volunteer donors for transfusion recipients is typically separated into its components: red blood cells, platelets, and plasma. Each of these fractions are individually stored and used to treat a multiplicity of specific conditions and disease states. For example, the red blood cell component is used to treat anemia, the concentrated platelet component is used to control bleeding, and the plasma component is used frequently as a source of Clotting Factor VIII for the treatment of hemophilia. Ideally, all blood cell preparations should be from freshly drawn blood and then immediately transfused to the recipient. However, the logistics of operating a blood donor center preclude this possibility in the vast majority of cases. Transfusions are needed day and night and it is difficult, if not impossible, to arrange for donor recruiting at unusual hours. Consequently, modern blood donor centers must use stored blood products. In the United States, blood storage procedures are subject to regulation by the government. The maximum storage periods for the blood components collected in these systems are specifically prescribed. For example, whole blood components collected in an "open" (i.e., non-sterile) system must, under governmental rules, be transfused within twenty-four hours and in most cases within six to eight hours. By contrast, when whole blood components are collected in a "closed" (i.e.. sterile) system the red blood cells can be stored up to forty-two days (depending upon the type of anticoagulant and storage medium used) and plasma may be frozen and stored for even longer periods.
While red cells are stored in the cold, Murphy and Gardner, New Eng. J. Med. 280:1094 (1969). demonstrated that platelets stored as platelet-rich plasma (PRP) at 22°C possessed a better in vivo half-life than those stored at 4°C. Thus, more acceptable platelet concentrates could be transfused after storage at room temperature. Until recently, the rules allowed for platelet concentrate storage at room temperature for up to seven days (depending upon the type of storage container). However, it was recognized that the incidence of bacterial growth and subsequent transfusion reactions in the recipient increased to unacceptable levels with a seven day old platelet concentrate. Platelet concentrates may now be stored for no more than five days. One might believe that it is a relatively simple matter to keep the blood preparation sterile during the manipulations needed to concentrate the platelets. After all, blood bags used for platelet concentrate preparation are in themselves sterile, as are the connected satellite bags. However, bacteria can be introduced by at least two different means.
First, if the donor is experiencing a mild bacteremia, the blood will be contaminated, regardless of the collection or storage method. Adequate donor histories and physicals will decrease but not eliminate this problem. See B.J. Grossman et al., Transfusion 31 :500 (1991).
A second, more pervasive source of contamination is the venepuncture. Even when "sterile" methods of skin preparation are employed, it is extremely difficult to sterilize the crypts around the sweat glands and hair follicles. During venepuncture, this contaminated skin is often cut out in a small "core" by a sharp needle. This core can serve to "seed" the blood bag with bacteria that may grow and become a risk to the recipient.
Indeed, many patients requiring platelet transfusions lack host-defense mechanisms for normal clearing and destruction of bacteria because of either chemotherapy or basic hematologic disease. The growth of even seemingly innocuous organisms in stored platelets can, upon transfusion, result in recipient reaction and death. See e.g., B.A. Myhre. JAMA 244:1333 (1980) and J.M. Heal et al. Transfusion 27:2 (1987).
The reports assessing the extent of contamination in platelets have differed in their methods, sample size, and bacterial detection schemes. D.H. Buchholz et al, Transfusion 13:268 (1973) reported an overall level of platelet contamination of 2.4% when a large
(>1000 bags) sample was examined and extensive measures were taken for bacterial culturing. While some units were heavily contaminated after just 24 hours of storage, the incidence as a whole varied according to the age of the concentrate and increased with the widespread
practice of pooling individual units; over 30% of pools were contaminated at 3 days. See also D.H. Buccholz et al. New Eng. J. Med. 285:429 (1971). While other clinicians suggest lower numbers, recent studies indicate that septic platelet transfusions are significantly underreported. See e.g., J.F. Morrow et al, JAMA 266:555 (1991). Pre-culturing platelets is not a solution to the bacterial contamination problem. The culture assay takes 48 hours to detect growth. Holding platelet units for an additional two days to await the results of the assay would create, ironically, a smaller margin of safety. See Table 2 in J.F. Morrow et al, JAMA 266:555 (1991). While heavily contaminated units would be detected at the outset, lightly contaminated units would be allowed to grow for two days. Older and potentially more contaminated units would end up being transfused.
Washing the blood cells (e.g., with saline) or filtering the bacteria are also not practical solutions. These techniques are time consuming and inefficient, as they can reduce the number of viable blood cells available for transfusion. Most importantly, they typically involve an "entry" into the storage system. Once an entry is made in a previously closed system, the system is considered "opened," and transfusion must occur quickly, regardless of the manner in which the blood was collected and processed in the first place.
Finally, antibiotics are not a reasonable solution. Contamination occurs from a wide spectrum of organisms. Antibiotics would be needed to cover this spectrum. Many recipients are allergic to antibiotics. In addition, there is an every increasing array of drug-resistant strains of bacteria that would not be inactivated.
In sum, there is a need for a means of inactivating bacteria from blood components prior to storage and transfusion in a way that lends itself to use in a closed system. This approach must be able to handle a variety of organisms without harm to the blood product or the transfusion recipient.
SUMMARY OF THE INVENTION
The invention generally relates to synthetic media for use with blood preparations intended for in vivo use, including synthetic media used in conjunction with the photodecontamination of platelets. By the term "synthetic media" the present invention intends to indicate aqueous solutions (e.g., phosphate buffered, aqueous salt solutions) other than those found as natural fluids (e.g., plasma, serum, etc.). However, it is not intended that such synthetic media be used without the benefit of natural fluids. Indeed, in preferred embodiments, mixtures of synthetic salt solutions and natural fluids are contemplated.
In one embodiment, the present invention contemplates a method of inactivating bacteria in platelet preparations for transfusions, comprising: a) providing, in any order, i) a phosphate buffered, aqueous salt solution comprising glucose and 8-methoxypsoralen; ii) means for activating 8-methoxypsoralen; and iii) a platelet preparation suspected of being contaminated with bacteria, comprising platelets and plasma; b) removing the plasma from the preparation and adding the solution to the platelets such that the platelets are suspended in a mixture having a residual plasma concentration between 8 and 25% by volume; and c) activating the 8-methoxypsoralen in the mixture with the activating means, so that the 8-methoxypsoralen inhibits the replication of the bacteria. In another embodiment, the method further comprises the step, after step c), of storing said mixture at approximately room temperature prior to transfusion.
With respect to other components of the solution, the present invention contemplates sodium citrate, sodium acetate, and mannitol. However, it is preferred that the solutions contain no sodium gluconate and no bicarbonate. The present invention contemplates that the activating means comprises a photoactivation device capable of emitting a given intensity of a spectrum of electromagnetic radiation comprising wavelengths between 180 nm and 400 nm, and in particular, between 320 nm and 380 nm. It is preferred that the intensity is less than 25 mW/cnr (e.g. between 10 and 20 mW/cnr) and that the mixture is exposed to this intensity for between one and twenty minutes (e.g. ten minutes).
In another embodiment, the present invention contemplates a method of inactivating bacteria in platelet preparations for transfusions, comprising: a) providing, in any order, i) a phosphate buffered, aqueous salt solution comprising approximately 2 mM glucose and 8-methoxypsoralen at a concentration between approximately 2 ug/ml and the maximum solubility of 8-methoxypsoralen in water; ii) means for activating the 8-methoxypsoralen; and iii) a platelet preparation suspected of being contaminated with bacteria, comprising platelets and plasma; b) removing the plasma from the preparation and adding the solution to said platelets such that said platelets are suspended in a mixture having a residual plasma concentration between 8 and 25% by volume; and c) activating the 8-methoxypsoralen in the mixture with the activating means, so that the 8-methoxypsoralen inhibits the replication of the bacteria.
By the phrase "the maximum solubility of 8-methoxypsoralen in water" the present invention intends a concentration derived experimentally in an aqueous solution in the absence
of organic solvents (e.g., DMSO, ethanol. etc.) at approximately room temperature. Concentrations exceeding this level are detected by the presence of precipitate, which is undesirable for intravenous infusion.
A saturated solution of 8-methoxypsoralen can be made by simply dissolving the compound (over a number of hours at room temperature) in distilled water until precipitate is apparent. If the solution is simply centrifuged, the supernatant can have a concentration of over 50 ug ml. On the other hand, if the solution is filtered (e.g., glass wool), the concentration of 8-methoxypsoralen has been found to be under 50 ug/ml. If, instead of centrifuging or filtering, the saturated solution is dialyzed against distilled water (over a number of days at room temperature), the compound is found to have a maximum solubility of approximately 39 ug/ml. It has been found that, when placed in a container to shield the compound from the light, a 0.9% NaCl solution of 8-methoxypsoralen at a concentration of 30 ug/ml is stable. It is preferred that the container is not glass (over time a ring opening reaction will occur which will decrease the concentration of the native compound). When weighing components, some experimental variability is expected. The present invention employs the term "approximately" to reflect this variability. This variability is typically plus or minus 5% and usually less than 10%.
In yet another embodiment, the present invention contemplates a method of inactivating bacteria in platelet preparations for transfusions, comprising: a) providing, in any order, i) an aqueous solution comprising glucose, sodium chloride, potassium chloride, magnesium chloride, monobasic and dibasic sodium phosphate, and 8-methoxypsoralen; ii) means for activating 8-methoxypsoralen; and iii) a platelet preparation suspected of being contaminated with bacteria, comprising platelets and plasma; b) removing the plasma from the preparation and adding the solution to the platelets such that the platelets are suspended in mixture having a residual plasma concentration between approximately 12 and 20% by volume; and c) activating the 8-methoxypsoralen in the mixture with the activating means, so that the 8-methoxypsoralen inhibits the replication of the bacteria.
In one embodiment, the present invention contemplates a synthetic platelet storage media, comprising an aqueous solution of: 45-100 mM sodium chloride: 4-5 mM potassium chloride; 10-15 mM sodium citrate; 20-27 mM sodium acetate; 2 mM glucose: 20-30 mM mannitol; 20 mM sodium phosphate; 2-3 mM magnesium chloride; and 8-methoxypsoralen.
The present invention contemplates a method of inactivating microorganisms in platelet preparations for subsequent transfusion, comprising: a) providing, in any order; i)
psoralen. ii) photoactivation means, and iii) a platelet preparation suspected of being contaminated with microorganisms, comprising platelets and plasma; b) adding said psoralen to said platelet preparation to create a solution of psoralen at a concentration; c) treating said solution with said photoactivation means so as to create a treated platelet preparation wherein said microorganisms are inactivated and wherein at least a portion of said psoralen concentration is free in said solution; and d) removing some of said free psoralen in said treated platelet preparation. As used herein, "removing some of said free psoralen" refers to the removal of at least a portion of the psoralen free in solution.
In one embodiment, the method further comprises the step, after step d), of storing said mixture at approximately room temperature prior to transfusion. Furthermore, in one embodiment, said activating means comprises a photoactivation device capable of emitting a given intensity of a spectrum of electromagnetic radiation comprising wavelengths between 320 nm and 380 nm; in certain embodiments, said intensity is less than 25 mW/cnr.
In additional embodiments, said mixture is exposed to said intensity for between one and ten minutes. In further embodiments, said removing of said free psoralen comprises contacting said platelets with a psoralen-binding polymer. When the removing comprises contacting, in some embodiments said contacting comprises transferring said platelets to a blood bag comprised of psoralen-binding polymer.
The present invention also contemplates a method of inactivating microorganisms in platelet preparation for transfusions, comprising: a) providing, in any order; i) psoralen, ii) synthetic media, iii) photoactivation means, and iv) a platelet preparation suspected of being contaminated with microorganisms, comprising platelets and plasma; b) removing a portion of said plasma from said preparation and adding said synthetic media containing said psoralen to said platelets such that said platelets are suspended in mixture having a residual plasma concentration; c) treating said mixture with said photoactivation means so as to create a treated platelet solution wherein said microorganisms are inactivated and wherein at least a portion of said psoralen concentration is free in said solution; and d) removing substantially all of said free psoralen in said treated platelet solution. As used herein, the phrase "removing substantially all of said free psoralen" refers to removing at least approximately 90% of said free psoralen. and preferably greater than approximately 99%.
In one embodiment, the method further comprises the step, after step d), of storing said mixture at approximately room temperature prior to transfusion. In another embodiment, said activating means comprises a photoactivation device capable of emitting a given intensity
of a spectrum of electromagnetic radiation comprising wavelengths between 320 nm and 380 nm; in certain embodiments, said intensity is less than 25 mW/cnr.
In additional embodiments, said mixture is exposed to said intensity for between one and ten minutes. In further embodiments, said removing of said free psoralen comprises contacting said platelets with a psoralen-binding polymer. When the removing comprises contacting, in some embodiments said contacting comprises transferring said platelets to a blood bag comprised of psoralen-binding polymer.
DESCRIPTION OF THE FIGURES Figure 1 is a perspective view of one embodiment of the device of the present invention.
Figure 2 is a cross-sectional view of the device shown in Figure 1 along the lines of
2-2.
Figure 3 is a cross-sectional view of the device shown in Figure 1 along the lines of
3-3. Figure 4 is a cross-sectional view of the device shown in Figure 1 along the lines of
4-4.
Figure 5 schematically shows the decontamination approach of the present invention applied specifically to blood products. Figure 6 is a graph showing the photoaddition of 8-methoxypsoralen to nucleic acid.
Figure 7 is a graph showing the degradation of 8-methoxypsoralen (8-MOP) compared to that of 4'-aminomethyl-4.5',8-trimethylpsoralen (AMT), as measured by HPLC. Figure 8 is a graph showing the inactivation of gram negative bacteria. Figure 9 is a graph showing pH results following treatment and platelet storage. Figure 10 is a graph showing aggregation results following treatment and platelet storage.
Figure 1 1 is a graph showing ATP results following treatment and platelet storage. Figure 12A schematically shows the standard blood product separation approach used presently in blood banks. Figure 12B schematically shows an embodiment of the present invention whereby synthetic media is introduced to platelet concentrate prepared as in Figure 12A.
Figure 12C schematically shows one embodiment of the decontamination approach of the present invention applied specifically to platelet concentrate diluted with synthetic media as in Figure 12B.
DESCRIPTION OF THE INVENTION
The invention generally relates to synthetic media for use with blood preparations intended for in vivo use. including synthetic media used in conjunction with the photodecontamination of platelets.
As noted previously, whole blood is collected and typically separated into red blood cells, platelets, and plasma. Each of these fractions are individually stored under specific conditions prior to in vivo use. In many cases, the extent of contamination is related to the storage time because of growth. A process that inactivated microorganisms at the time of blood collection would be expected to prevent growth during storage.
In one embodiment, the present invention contemplates inactivating blood products after separation but before storage. In this embodiment, a nucleic acid binding compound is selectively employed to treat contamination by microorganisms.
In one embodiment, the nucleic acid binding compound is selected from the group comprising furocoumarins. In a preferred embodiment, the furocoumarin is a psoralen that is activated by a photoactivation device. Psoralens are tricyclic compounds formed by the linear fusion of a furan ring with a coumarin. Psoralens can intercalate between the base pairs of double-stranded nucleic acids, forming covalent adducts to pyrimidine bases upon absorption of longwave ultraviolet light (UVA). G.D. Cimino et al, Ann. Rev. Biochem. 54:1151 (1985); and Hearst et al.. Quart. Rev. Biophys. 17:1 (1984). If there is a second pyrimidine adjacent to a psoralen-pyrimidine monoadduct and on the opposite strand, absorption of a second photon can lead to formation of a diadduct which functions as an interstrand crosslink. S.T. Isaacs et al. Biochemistry 16: 1058 (1977); S.T. Isaacs et al. Trends in Photobiology (Plenum) pp. 279-294 (1982); J. Tessman et al, Biochem. 24:1669 (1985); and Hearst et al, U.S. Patents Nos. 4.124,589, 4.169.204. and 4.196,281. hereby incorporated by reference. Psoralens have been shown to inactivate viruses in some blood products. See H.J.
Alter et al. The Lancet (ii:1446) (1988); L. Lin et al. Blood 74:517 (1989); and G.P. Wiesehahn et al, U.S. Patents Nos. 4,727,027 and 4,748,120. hereby incorporated by reference, describe the use of a combination of 8-methoxypsoralen (8-MOP) and irradiation.
They show that 300 ug/ml of 8-MOP together with one hour or more of irradiation with ultraviolet light can effectively inactivate viruses. However, these treatment conditions cause harm to the blood product because of energy transfer. Their approach is only feasible if the damage to cells is specifically suppressed by limiting the concentration of molecular oxygen. a difficult and expensive process.
The inactivation method of the present invention provides a method of inactivating single cell and multicellular organisms, and in particular, bacteria, fungi, mycoplasma and protozoa. In contrast to previous approaches, the method of the present invention does not cause harm to the blood product. There is no significant damage to cells and, therefore, no need to limit the concentration of molecular oxygen.
The present invention contemplates using much lower concentrations of nucleic acid binding compounds than previously employed. For example, the present invention contemplates using 8-MOP at concentrations of 30 ug/ml or less. Indeed, a preferred concentration of 8-MOP for bacterial decontamination in platelet concentrates is 3 ug/ml or less. i.e.. a one hundred-fold lower concentration than employed by G.P. Wiesehahn et al., supra. Because lower concentrations are employed, solvents like DMSO (used to increase the solubility of 8-MOP) are unnecessary.
The present invention, furthermore, contemplates using much lower doses of irradiation than previously described. This is accomplished with lower intensity irradiation sources, with wavelength cutoff filters (see below), and/or shorter irradiation times. In a preferred embodiment, the time of irradiation is variable and controlled from 1 second to 99 minutes, in one second increments.
In one embodiment, the device of the present invention is mounted on an agitator, giving horizontal unidirectional and sinusoidal motion of variable frequency and amplitude. In another embodiment, heat from the lamps, ballasts and other sources is blocked from the bags.
While it is not intended that the present invention be limited by the theory of inactivation. the use of lower compound concentrations and irradiation doses comes from and understanding that, where the present invention is applied to the decontamination of a single cell or multicellular organism (as opposed to a virus), a lower level of nucleic acid binding will achieve inactivation. In addition, it is recognized that it is not essential that inactivation be complete. That is to say, partial inactivation will be adequate as long as the viable portion is unable, within the storage period, to grow to levels sufficient to cause disease.
To appreciate that, in any given case, an inactivation method may or may not achieve complete inactivation, it is useful to consider a specific example. A bacterial culture is said to be sterilized if an aliquot of the culture, when transferred to a fresh culture plate and permitted to grow, is undetectable after a certain time period. The time period and the growth conditions (e.g., temperature) define an "amplification factor". This amplification factor along with the limitations of the detection method (e.g., visual inspection of the culture plate for the appearance of a bacterial colony) define the sensitivity of the inactivation method. A minimal number of viable bacteria must be applied to the plate for a signal to be detectable. With the optimum detection method, this minimal number is 1 bacterial cell. With a suboptimal detection method, the minimal number of bacterial cells applied so that a signal is observed may be much greater than 1. The detection method determines a "threshold" below which the method appears to be completely effective (and above which the method is. in fact, only partially effective).
This interplay between the amplification factor of an assay and the threshold that the detection method defines, can be illustrated. For example, bacterial cells can be applied to a plate; the detection method is arbitrarily chosen to be visual inspection. Assume the growth conditions and time are such that an overall amplification of 104 has occurred. The detectable signal will be proportional to the number of bacterial cells actually present after amplification. For calculation purposes, the detection threshold is taken to be 106 cells; if fewer than 106 cells are present after amplification, no cell colonies are visually detectable and the inactivation method will appear effective. Given the amplification factor of 104 and a detection threshold of 106. the sensitivity limit would be 100 bacterial cells; if less than 100 viable bacterial cells were present in the original aliquot of the bacterial culture after the sterilization method is performed, the culture would still appear to be sterilized. Such a situation is common for bacterial growth assays. The sensitivity of the assay is such that viable bacterial cells are present but the assay is unable to detect them. This may explain, at least in part, the variability in results obtained by researchers attempting to determine the extent of bacterial contamination of blood products. See D.H. Buchholz, et al. Transfusion 13:268 (1973), wherein such variability is discussed. It should be noted that, in many countries, contamination of blood products by cellular organisms is more pervasive and, therefore, more serious than viral contamination. For example, in South America, the most important blood-borne organism is T. cruzi. which is the etiologic agent of Chagas disease. Approximately 16-18 million people are infected in the
Americas (including 11% of the population of Chile). It is contemplated that the decontamination method of the present invention is well-suited for inactivation of this protozoa.
The present invention contemplates specific synthetic media formulations for use with blood preparations. The formulations of the present invention are particularly useful for platelet storage. These formulations are also useful when employed in conjunction with the photodecontamination of platelets.
While synthetic media have not previously been employed in conjunction with photodecontamination, synthetic media formulations have been described for platelet storage. For example, U.S. Patent No. 4,828,976 to Murphy stresses the importance of having a synthetic blood platelet storage medium that is essentially free of glucose and calcium. The specification notes that glucose consumption and lactate production continue as long as glucose is present at the concentration above 1.5 mM (Col. 12. line 13). Lactate production is thought to be the cause of loss of pH stability and consequent impairment of platelet function. See also U.S. Patent No. 4,925,665 and U.S. Patent No. 4.992,363.
U.S. Patent No. 4,447,415 to Rock describes a synthetic medium consisting essentially of: a balanced, physiologically compatible, saline solution: an anticoagulant; and one or more additives to enhance stability of the platelets selected from: (a) nutrients to improve the storage life of the platelets; (b) reversible inhibitors for platelet activation: (c) substances to raise cyclic adenosine monophosphate levels which have reversible effects on platelets; and
(d) buffering agents which are physiologically compatible. The specification stresses the need to remove plasma. The specification indicates that this is achieved either by centrifugation and washing, or by "extraction" (see Examples 1 and 2 of the '415 patent). See also U.S. Patent No. (Reissue) 32,874. U.S. Patent No. 4,704,352 to Miripol discloses a medium which contains either magnesium L-ascorbate-2-phosphate or calcium L-ascorbate-2-phosphate. U.S. Patent No. 4.695,460 to Holme describe media that contain sodium bicarbonate. U.S. Patent No. 4.390,619 to Harmening-Pittiglio discloses a media capable of supporting platelet metabolism, containing a water-insoluble polymer containing releasable phosphate or bicarbonate ions. In contrast to these previous attempts, the formulations of the present invention: i) contain glucose; ii) utilize residual plasma; and iii) avoid bicarbonate. It has been found that glucose is indeed beneficial as an element in the synthetic media. With respect to plasma, the present invention contemplates that a standard plasma expression method (e.g., such as
currently used in most blood banks) will be used, such that platelets are suspended in a residual plasma concentration between 8 and 25% by volume, and more commonly 12 to 20%. Bicarbonate has been found to be extremely difficult to control in a system employing gas permeable blood bags. The present invention therefore contemplates a phosphate buffer to control the pH of the blood preparation.
The present invention contemplates devices and methods for photoactivation and specifically, for activation of photoreactive nucleic acid binding compounds. The present invention contemplates devices having an inexpensive source of electromagnetic radiation that is integrated into a unit. In general, the present invention contemplates a photoactivation device for treating photoreactive compounds, comprising: a) means for providing appropriate wavelengths of electromagnetic radiation to cause activation of at least one photoreactive compound: b) means for supporting a plurality of blood products in a fixed relationship with the radiation providing means during activation: and c) means for maintaining the temperature of the blood products within a desired temperature range during activation. The present invention also contemplates methods, comprising: a) supporting a plurality of blood product containers, containing one or more photoreactive compounds, in a fixed relationship with a fluorescent source of electromagnetic radiation; b) irradiating the plurality of blood products simultaneously with said electromagnetic radiation to cause activation of at least one photoreactive compound; and c) maintaining the temperature of the blood products within a desired temperature range during activation.
The major features of one embodiment of the device of the present invention involve: A) an inexpensive source of ultraviolet radiation in a fixed relationship with the means for supporting the sample vessels; B) rapid photoactivation; C) large sample processing; D) temperature control of the irradiated samples; and E) inherent safety.
A. Electromagnetic Radiation Source
A preferred photoactivation device of the present invention has an inexpensive source of ultraviolet radiation in a fixed relationship with the means for supporting the sample vessels. Ultraviolet radiation is a form of energy that occupies a portion of the electromagnetic radiation spectrum (the electromagnetic radiation spectrum ranges from cosmic rays to radio waves). Ultraviolet radiation can come from many natural and artificial sources. Depending on the source of ultraviolet radiation, it may be accompanied by other (non-ultraviolet) types of electromagnetic radiation (e.g., visible light).
Particular types of ultraviolet radiation are herein described in terms of wavelength. Wavelength is herein described in terms of nanometers ("nm"; 10"9 meters). For purposes herein, ultraviolet radiation extends from approximately 180 nm to 400 nm. When a radiation source, by virtue of filters or other means, does not allow radiation below a particular wavelength (e.g., 320 nm), it is said to have a low end "cutoff at that wavelength (e.g., "a wavelength cutoff at 300 nanometers"). Similarly, when a radiation source allows only radiation below a particular wavelength (e.g., 360 nm), it is said to have a high end "cutoff at that wavelength (e.g., "a wavelength cutoff at 360 nanometers").
For any photochemical reaction it is desired to eliminate or least minimize any deleterious side reactions. Some of these side reactions can be caused by the excitation of endogenous chromophores that may be present during the photochemical activation procedure. In a system where only nucleic acid and psoralen are present, the endogenous chromophores are the nucleic acid bases themselves. Restricting the activation process to wavelengths greater than 320 nm minimizes direct nucleic acid damage since there is very little absorption by nucleic acids above 313 nm.
In blood products, the nucleic acid is typically present together with additional biological chromophores. If the biological fluid is just protein, the 320 nm cutoff will be adequate for minimizing side reactions (aromatic amino acids do not absorb above 320 nm). If the biological fluid includes cells and/or cellular constituents, there will be many other chromophores, including hemes and flavins.
Hemes are abundant in blood products where they arise from the lysis of red cells. Flavins, like hemes. are required for metabolic respiration. Both of these endogenous chromophores will cause damage to cells if excited by photoirradiation.
Hemes have three principle absorption bands: two are in the red region of the visible spectrum; the other is centered about 400 nm. Flavins have two principle absorption peaks: one at 450 nm and the other at 370 nm.
In view of the presence of these endogenous chromophores in blood products, it is intended that the device of the present invention be designed to allow for irradiation within a small range of specific and desirable wavelengths, and thus avoid damage to cells caused by energy transfer. The preferred range of desirable wavelengths is between 320 and 350 nm. Some selectivity can be achieved by choice of commercial irradiation sources. For example, while typical fluorescent tubes emit wavelengths ranging from 300 nm to above 400
nm (with a broad peak centered around 360 nm), BLB type fluorescent lamps are designed to remove wavelengths above 400 nm. This, however, only provides an upper end cutoff.
In a preferred embodiment, the device of the present invention comprises an additional filtering means. In one embodiment, the filtering means comprises a glass cut-off filter, such as a piece of Cobalt glass. In another embodiment, the filtering means comprises a liquid filter solution that transmit only a specific region of the electromagnetic spectrum, such as an aqueous solution of Co(No3)2. This salt solution yields a transmission window of 320-400 nm. In a preferred embodiment, the aqueous solution of Co(No3)2 is used in combination with NiSO4 to remove the 365 nm component of the emission spectrum of the fluorescent or arc source employed. The Co-Ni solution preserves its initial transmission remarkably well even after tens of hours of exposure to the direct light of high energy sources.
It is not intended that the present invention be limited by the particular filter employed. Several inorganic salts and glasses satisfy the necessary requirements. For example, cupric sulfate is a most useful general filter for removing the infra-red, when only the ultraviolet is to be isolated. Its stability in intense sources is quite good. Other salts are known to one skilled in the art. Aperture or reflector lamps may also be used to achieve specific wavelengths and intensities.
When ultraviolet radiation is herein described in terms of irradiance. it is expressed in terms of intensity flux (milliwatts per square centimeter or "mW cm'2"). "Output" is herein defined to encompass both the emission of radiation (yes or no; on or off) as well as the level of irradiance. In a preferred embodiment, intensity is monitored at 4 locations: 2 for each side of the plane of irradiation.
A preferred source of ultraviolet radiation is a fluorescent source. Fluorescence is a special case of luminescence. Luminescence involves the absorption of electromagnetic radiation by a substance and the conversion of the energy into radiation of a different wavelength. With fluorescence, the substance that is excited by the electromagnetic radiation returns to its ground state by emitting a quantum of electromagnetic radiation. While fluorescent sources have heretofore been thought to be of too low intensity to be useful for photoactivation. in one embodiment the present invention employs fluorescent sources to achieve results thus far achievable on only expensive equipment.
As used here, fixed relationship is defined as comprising a fixed distance and geometry between the sample and the light source during the sample irradiation. Distance relates to the distance between the source and the sample as it is supported. It is known that
light intensity from a point source is inversely related to the square of the distance from the point source. Thus, small changes in the distance from the source can have a drastic impact on intensity. Since changes in intensity can impact photoactivation results, changes in distance are avoided in the devices of the present invention. This provides reproducibility and repeatability.
Geometry relates to the positioning of the light source. For example, it can be imagined that light sources could be placed around the sample holder in many ways (on the sides, on the bottom, in a circle, etc.). The geometry used in a preferred embodiment of the present invention allows for uniform light exposure of appropriate intensity for rapid photoactivation. The geometry of a preferred device of the present invention involves multiple sources of linear lamps as opposed to single point sources. In addition, there are several reflective surfaces and several absorptive surfaces. Because of this complicated geometry, changes in the location or number of the lamps relative to the position of the samples to be irradiated are to be avoided in that such changes will result in intensity changes.
B. Rapid Photoactivation
The light source of the preferred embodiment of the present invention allows for rapid photoactivation. The intensity characteristics of the irradiation device have been selected to be convenient with the anticipation that many sets of multiple samples may need to be processed. With this anticipation, a fifteen minute exposure time or less is a practical goal. In designing the devices of the present invention, relative position of the elements of the preferred device have been optimized to allow for fifteen minutes of irradiation time, so that, when measured for the wavelengths between 320 and 350 nanometers, an intensity flux greater than approximately 1 mW cm'2 is provided to the sample vessels. In a preferred embodiment, the device irradiates both sides of the bag.
C. Processing of Large Numbers of Samples
As noted, another important feature of the photoactivation devices of the present invention is that they provide for the processing of large numbers of samples. In this regard, one element of the devices of the present invention is a means for supporting a plurality of blood products, and in particular, blood bags. In the preferred embodiment of the present invention the supporting means comprises glass plates between two banks of lights with a capacity of six 50 ml bags (equivalent to Dupont Stericell bag) plus connectors and tubing, at
one time. By accepting commonly used commercially available blood bags, the device of the present invention allows for convenient processing of large numbers of samples.
D. Temperature Control As noted, one of the important features of the photoactivation devices of the present invention is temperature control. Temperature control is important because the temperature of the sample in the sample at the time of exposure to light can dramatically impact the results. For example, conditions that promote secondary structure in nucleic acids also enhance the affinity constants of many psoralen derivatives for nucleic acids. Hyde and Hearst, Biochemistry, 17, 1251 (1978). These conditions are a mix of both solvent composition and temperature. With single stranded 5S ribosomal RNA, irradiation at low temperatures enhances the covalent addition of HMT to 5S rRNA by two fold at 4°C compared to 20°C. Thompson et al. J. Mol. Biol. 147:417 (1981). Even further temperature induced enhancements of psoralen binding have been reported with synthetic polynucleotides. Thompson et al. Biochemistry 21 :1363 (1982).
With respect to bacteria, it should be noted that repair of crosslinks occurs during irradiation. However, where a lower temperature is employed during irradiation, the bacterial repair process is suppressed. Thus, a 15°C irradiation has a significant effect on the level of inactivation that is observed.
E. Inherent Safety
Ultraviolet radiation can cause severe burns. Depending on the nature of the exposure, it may also be carcinogenic. The light source of a preferred embodiment of the present invention is shielded from the user. This is in contrast to the commercial hand-held ultraviolet sources as well as the large, high intensity sources. In a preferred embodiment, the irradiation source is contained within a housing made of material that obstructs the transmission of radiant energy (i.e., an opaque housing). No irradiation is allowed to pass to the user. This allows for inherent safety for the user.
EXPERIMENTAL
In the experimental disclosure which follows, the following abbreviations apply: eq (equivalents); M (Molar); μM (micromolar); N (Normal); mol (moles); mmol (millimoles); μmol (micromoles); nmol (nanomoles); gm (grams); mg (milligrams); μg (micrograms); L (liters); ml (milliliters); μl (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); °C (degrees Centigrade); HPLC (High Pressure Liquid Chromatography).
In some of the examples below, phosphate buffered synthetic media is formulated for platelet storage and treatment. In some cases, it may be convenient to make up the formulation in two steps. For example, in the preparation of S 2.22, a monobasic phosphate solution can be prepared as the first step:
MONOBASIC PHOSPHATE SOLUTION
23 mM Na gluconate (MW 218.2) 5.019 grams
20 mM Na acetate (MW 82.03) 1.641 grams
2 mM Glucose (MW 180.16) 0.360 grams
5 mM D-mannitol (MW 182) 0.910 grams
5 mM KC1 (MW 74.56) 0.373 grams
47 mM NaCl (MW 58.44) 2.747 grams
15 mM Na Citrate (MW 294.10) 4.412 grams
20 mM NaH2PO4*H,O (MW 137.99) 2.760 grams
Distilled water is added to make 1 liter, the solution is mixed, sterile filtered (0.2 micron filter) and refrigerated.
At the same time, a dibasic phosphate solution is prepared as a second step:
DIBASIC PHOSPHATE SOLUTION
23 mM Na gluconate (MW 218.2) 5.019 grams
20 mM Na acetate (MW 82.03) 1.641 grams
2 mM Glucose (MW 180.16) 0.360 grams
5 mM D-mannitol (MW 182) 0.910 grams
5 mM KC1 (MW 74.56) 0.373 grams
47 mM NaCl (MW 58.44) 2.747 grams
15 mM Na Citrate (MW 294.10) 4.412 grams
20 mM Na,HPO4 (MW 142.0) 2.840 grams
As was done with the monobasic solution, distilled water is added to make 1 liter, the solution is mixed, sterile filtered (0.2 micron filter) and refrigerated.
When the media is needed to suspend platelets, the monobasic solution is added to the dibasic solution to a pH of 7.4.
Alternatively, the media can be made in one step. For example, S. 4.0 can be made in one step, resulting in a pH balanced solution (e.g., pH 7.2), by combining the following reagents in 2 liters of distilled water:
Preparation of S.4.0
Formula W. mMolarity Grams/2Liters
NaAcetate*3H,O 136.08 20 5.443
Glucose 180.16 2 0.721
D-mannitol 182.17 20 7.287
KC1 74.56 4 0.596
NaCl 58.44 90 10.519
Na3 Citrate 294.10 10 5.882
Na,HPO4*7H:O 268.07 14.46 7.752
NaH,PO4*H,O 137.99 5.54 1.529
MgCl,*6H O 203.3 2 0.813
As with other formulations, the solution is mixed, sterile filtered (0.2 micron filter) and refrigerated.
The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
EXAMPLE 1
As noted above, the present invention contemplates devices and methods for the activation of photoreactive nucleic acid binding compounds. In this example, a photoactivation device is described for decontaminating blood products according to the method of the present invention. This device comprises: a) means for providing appropriate wavelengths of electromagnetic radiation to cause activation of at least one photoreactive compound: b) means for supporting a plurality of blood products in a fixed relationship with the radiation providing means during activation; and c) means for maintaining the temperature of the blood products within a desired temperature range during activation.
Figure 1 is a perspective view of one embodiment of the device integrating the above-named features. The figure shows an opaque housing (100) with a portion of it removed, containing an array of bulbs (101) above and below a plurality of representative
blood product containing means (102) placed between plate assemblies (103. 104). The plate assemblies (103, 104) are described more fully, subsequently.
The bulbs (101). which are connectable to a power source (not shown), serve as a source of electromagnetic radiation. While not limited to the particular bulb type, the embodiment is configured to accept an industry standard, dual bipin lamp.
The housing (101) can be opened via a latch (105) so that the blood product can be placed appropriately. As shown in Figure 1 , the housing (100), when closed, completely contains the irradiation from the bulbs (101). During irradiation, the user can confirm that the device is operating by looking through a safety viewport (106) which does not allow transmission of ultraviolet light to the user.
The housing (100) also serves as a mount for several electronic components on a control board (107), including, by way of example, a main power switch, a count down timer, and an hour meter. For convenience, the power switch can be wired to the count down timer which in turn is wired in parallel to an hour meter and to the source of the electromagnetic radiation. The count down timer permits a user to preset the irradiation time to a desired level of exposure. The hour meter maintains a record of the total number of radiation hours that are provided by the source of electromagnetic radiation. This feature permits the bulbs
(101) to be monitored and changed before their output diminishes below a minimum level necessary for rapid photoactivation. Figure 2 is a cross-sectional view of the device shown in Figure 1 along the lines of
2—2. Figure 2 shows the arrangement of the bulbs (101) with the housing (100) opened. A reflector (108A. 108B) completely surrounds each array of bulbs ( 101). Blood product containing means (102) are placed between upper (103) and lower ( 104) plate assemblies. Each plate assembly is comprised of an upper (103 A, 104A) and lower (103B, 104B) plates. The plate assemblies (103, 104) are connected via a hinge (109) which is designed to accommodate the space created by the blood product containing means (102). The upper plate assembly (103) is brought to rest gently on top of the blood product containing means
(102) supported by the lower plate (104B) of the lower plate assembly (104).
Detectors (1 10A, HOB, HOC. HOD) may be conveniently placed between the plates (103A. 103B, 104A, 104B) of the plate assemblies (103, 104). They can be wired to a printed circuit board (111) which in turn is wired to the control board (107).
Figure 3 is a cross-sectional view of the device shown in Figure 1 along the lines of 3—3. Six blood product containing means (102) (e.g., Teflon™ platelet unit bags) are placed
in a fix relationship above an array of bulbs (101). The temperature of the blood product can be controlled via a fan (112) alone or, more preferably, by employing a heat exchanger (113) having cooling inlet (114) and outlet (115) ports connected to a cooling source (not shown). Figure 4 is a cross-sectional view of the device shown in Figure 1 along the lines of 4—4. Figure 4 more clearly shows the temperature control approach of a preferred embodiment of the device. Upper plate assembly plates (103 A. 103B) and lower plate assembly plates (104A, 104B) each create a temperature control chamber (103C. 104C), respectively. The fan (112) can circulate air within and between the chambers (103C. 104C). When the heat exchanger (113) is employed, the circulating air is cooled and passed between the plates (103 A. 103B, 104A, 104B).
EXAMPLE 2
Figure 5 shows an embodiment wherein platelets are treated by the method of the present invention. Following fractionation, platelets are transferred to a bag containing a nucleic acid binding compound (shown in Figure 5 as a shaded bag). This bag, which has transmission properties and other characteristics suited for the present invention. is then placed in an irradiation device (such as that described in Example 1. above) and is irradiated. The free compound may be collected or "captured" as desired by a capture device. In such a case, the bag would contain only compound that is contained in cells; the bag would have no free compound (this bag is indicated in Figure 5 as unshaded).
In one capture approach, a bag comprised of a psoralen-binding polymer is employed to capture the compound. The Cutter CLX bag has been found to have this property.
EXAMPLE 3 In this example, the decontamination methods of the present invention are applied to inactivate Klebsiella pneumoniae, which is known to be among the organisms associated with bacteremia. See generally, Infect. Control 5:343 (1984). The particular isolate in this case was obtained following a platelet transfusion where the recipient immediately went into shock and later died. The platelet bag was obtained and cultured, and the organism was identified and sero typed.
For the experiment, the strain was kept at ambient temperature and inoculated onto either heart infusion agar (HIA) or heart infusion agar containing 5% (v/v) sheep blood (BAP) by swabbing each plate for confluency via a sterile applicator swab. Cultures were then
incubated under static conditions for 16 - 18h at 35°C. At the end of the incubation period, cultures were removed and suspended in phosphate buffered saline (PBS;pH 7.2-7.4) and spectrophotometrically standardized to 1.0 at an OD610 using a Spectronic 501 or 601 spectrophotometer (Bausch and Lomb). After standardization, suspensions were diluted 1 :10 in PBS to achieve an ca. 108 CFU/ml concentration. This standardized suspension is then split to use an aliquot for the inactivation study, while another portion was plated in duplicate 10-fold serial dilutions onto HIA (or BAP) to ensure appropriate concentrations of the organism.
To assess inactivation of the organism,, two ABO compatible freshly outdated human platelet concentrate units were obtained from the Blood Bank of Alameda - Contra Costa
Medical Association. They were pooled and redivided into two bags. One bag was infused with the bacteria preparation. The platelets in the second unit were pelleted at 4000 xg for 6 minutes and then resuspended in a medium containing 85% saline and 15%) plasma. Bacteria was added after platelets were well resuspended. 3 ml aliquots of bacteria containing platelet concentrate were transferred to a Teflon™ minibag (American Fluoroseal Corporation, Silver Spring, Maryland) and received specified amounts of 8-MOP and UVA irradiation, except for the controls, which were irradiated without psoralen. or received no treatment. Temperature was maintained at 25°C during irradiation in the irradiation device described above which is equipped with an air cooling mechanism.
F24T 12-BL-HO fluorescent lamps were used. These are high output "black light" tubes (engineered to emit specific wavelengths by means of an internal phosphor coating) 24 inches in length. Total intensity is less than 25 mw/cnr and typically between 15 and 20 mw/cπr. Following irradiation, bacteria were quantified by plating 0.1 ml of serial 10-fold dilutions in broth onto 100 mm petri dishes containing BHI agar. After 24 hr incubation at 35°C. colonies were counted and bacterial concentration was calculated on a per ml basis. The results (Figure 8) show that while only 1.2 logs of Klebsiella were killed by 5 μg/ml 8-MOP in five minutes of UVA irradiation in 100% plasma, more than 6.5 logs were killed under the same conditions in 15% plasma and 85% saline.
While not limited to any theory as to the mechanism by which this improvement in decontamination efficiency was achieved, it would appear that these results indicate that either that the optical properties of the synthetic medium are better, or the lower protein
concentration allows for a higher concentration of free 8-MOP. In the latter situation, the 8-MOP would be more available for decontamination.
EXAMPLE 4 Artuc and co-workers examined the solubility of 8-MOP in human and bovine serum proteins. They showed that, when working with 8-MOP concentrations ranging from 100 to 1000 ng/ml in serum. 75% to 80% of the 8-MOP was bound to albumin. M. Artuc et al, Brit. J. Derm. 101 :669 (1979).
In this example, the binding of 8-MOP to Calf Thymus DNA is compared using plasma and a protein free media in order to validate the efficiency of psoralen-nucleic interactions under the decontamination methods of the present invention. Although this measurement used eukaryotic nucleic acid rather than bacterial nucleic acid, it is a useful indicator of the degree of adduct formation for bacteria.
Η-8-MOP was prepared to a concentration of 115 ug/ml in ethanol at a specific activity of 4.7 x 106 CPM/microgram (hereinafter "8-MOP stock"). Thereafter 130.5 or 22 ul of 8-MOP stock (2 each) for samples containing DNA ("+ DNA") and 52.2 or 8.7 ul for samples not containing DNA ("- DNA") were dried down. To + DNA samples. 40 ul of DNA stock (7.7 mg/ml) was added as well as either 460 ul plasma (day old frozen) or 450 ul Tris-EDTA ("TE") buffer. To the latter was also added 10 ul 5M NaCl. For - DNA samples (i.e., the controls), 184 ul plasma and 16 ul water was added.
The samples were mildly vortexed for approximately one hour and the counts were checked to confirm that the 8-MOP dissolved.
Each sample (100 ul) was irradiated on an HRI-100 (HRI Research Inc.. Concord. CA) at 25 °C for 0. 2. 4, 8, and 16 minutes. Samples were kept at 4°C overnight after irradiation. Thereafter, the samples were extracted. First, a phenol solution was prepared at pH 8 by equilibrating with 0.1 M Tris pH 8. Each sample was then extracted with 100 ul phenol. Each sample was centrifuged for 5 minutes to remove the aqueous phase to a new tube. A second extraction was performed with 100 ul 1 :1 phenolxhloroform. A final extraction was performed with 100 ul chloroform. The final aqueous phase was precipitated by adding 50 ul NaCl adjusted to give a final concentration of NaCl of 0.2 M and then adding 250 ul ethanol. The samples were again centrifuged (10 minutes). The supernatant was removed and the pellets were dried. The pellets were resuspended in 100 ul TE and reprecipitated. This was repeated for a total of 3
precipitations. The final pellets were brought up in 600 ul water and 100 ul was counted. Each sample was assayed for DNA by measuring absorbance (260 nm). 8-MOP levels were plotted as adducts per 1000 base pairs ("8-MOP:kBP").
The results (Figure 6) show that plasma does significantly change the addition kinetics of 8-MOP to DNA. Addition to nucleic acid is much better in the protein free media.
The frequency of 8-MOP-DNA adduct formation in protein free media predicts a high multiplicity of modification of the bacterial genome. Furthermore, this type of biochemical measurement has the potential to provide a means to monitor the efficiency of the photochemical inactivation method.
EXAMPLE 5
Photoactivation of psoralens and isopsoralens may result in a variety of photoproducts. "Photoproduct" is best understood by considering the possible reactions of photoreactive compound when exposed to activating wavelengths of electromagnetic radiation. While not limited to any precise mechanism, it is believed that the reaction of photoreactive compound in its ground state ("C") with activating wavelengths of electromagnetic radiation creates a short-lived excited species ("C*"):
c →
What happens next is largely a function of what potential reactants are available to the excited species. Since it is short-lived, a reaction of this species with nucleic acid ("NA") is believed to only be possible if nucleic acid is present at the time the excited species is generated. Thus, the reaction must, in operational terms, be in the presence of activating wavelengths of electromagnetic radiation, i.e., it is "photobinding"; it is not dark binding. The reaction can be depicted as follows:
C* + NA → NA:C
The product of this reaction is hereinafter referred to as "Photoaddition Product" and is to be distinguished from "Photoproduct."
With this reaction described, one can now consider the situation where nucleic acid is not available for binding at the time the compound is exposed to activating wavelengths of
electromagnetic radiation. Since the excited species is short-lived and has no nucleic acid to react with, the excited species may simply return to its ground state:
On the other hand, the excited species may react with itself (i.e.. a ground state or excited species) to create a ground state complex ("C:C"). The product of these self-reactions where two compounds react is referred to as "photodimer" or simply "dimer." The self-reactions, however, are not limited to two compounds; a variety of multrimers may be formed (trimers, etc.).
The excited species is not limited to reacting with itself. It may react with its environment, such as elements of the solvent ("E") (e.g., ions, gases, etc.) to produce other products:
C* + E → E:C
It is this type of reaction that is believed to cause cellular damage (e.g.,, reaction with oxygen to create singlet oxygen species). Furthermore, it may simply internally rearrange ("isomerize") to a ground state derivative ("["):
C* → [
Finally, the excited species may undergo other reactions than described here.
The present invention and the understanding of "photoproduct" does not depend on which one (if any) of these reactions actually occurs. "Photoproduct" - whatever its nature - is deemed to exist if, following the reaction of a compound and activating wavelengths of electromagnetic radiation, there is a resultant product formed that can interact with other components of the reaction environment.
With psoralens such as 4'-hydroxymethyl-4,5'.8-trimethylpsoralen (HMT), there are a number of resultant products produced when the HMT is exposed to activating wavelengths of electromagnetic radiation. The major resultant products of HMT are two cyclobutyl photodimers. In one of the dimers, the two pyrone rings are linked in a cis-syn configuration, while in the other dimer. the linkage occurs between the furan end of one molecule and the
pyrone end of the other, again with cis-syn configuration. A third resultant product of HMT is a monomeric HMT photoisomer. In this isomer. the central ring oxygens assume a 1, 4 instead of the normal 1. 3 orientation. While the two photodimers would not be expected to have an intercalating activity due to geometrical considerations, the photoisomer remains planer, and accordingly, it is contemplated that it has a positive intercalative association with double stranded nucleic acid and. thus, could be a mutagen.
In this example, the photochemical breakdown of 8-MOP is compared with AMT.
The samples were analyzed by reverse phase HPLC using a Rainen Dynamax 300A column.
Gradient elution was performed with 0.1 M ammonium acetate / acetonitrile (0 - 70% acetonitrile over 42 minutes). AMT elutes as a single peak at approximately 24 minutes under these conditions. Detection was by absorption at either 260 or 330 nm. The latter wavelength was used for the plasma containing samples.
Standard solutions of each compound were prepared at various concentrations. These solutions were then diluted 1 : 10 into water, then 300 ul injected for analysis. All samples were monitored at 300 nm. Peaks were analyzed by measuring either peak height or peak area, then converted to a gh ml value using the standard plot. Peak area was determining by photocopying the trace, cutting out the copy of the peak, then weighing the resultant trace.
The two methods gave essentially the same result.
The results are shown in Figure 7. Clearly, AMT degrades more quickly than 8-MOP. It would, therefore, be expected to generate more photoproducts - which eventually would end up in the transfusion recipient. By contrast, it is not expected that 8-MOP generates a significant amount of photoproducts. This is important when one considers that the weight of authority has concluded that unactivated 8-MOP is nonmutagenic.
EXAMPLE 6
When platelets become activated, an alpha granule membrane glycoprotein called GMP140 becomes exposed on the platelet surface. Less than (5%) of fresh, normal unstimulated platelets express detectable GMP140 levels by flow cytometry. See generally M.J. Metzelaar. Studies on the Expression of Activation-Markers on Human Platelets (Thesis 1991).
To measure GMP140. a small aliquot of platelet rich plasma is placed in HEPES buffer containing a GMP140-binding antibody or control mouse IgG. CD62 is a commercially available monoclonal antibody which binds to GMP140 (available from Sanbio.
Uden. the Netherlands: Caltag Labs. So. San Francisco. CA. and Becton Dickinson. Mountain View, CA). After a fifteen minute incubation at room temperature. Goat Anti-Mouse IgG conjugated to FITC is added to the tube in saturating amounts and allowed to incubate at room temperature (RT) for 15 minutes. Finally, the cells are diluted in isotonic saline, fixed with paraformaldehyde and analyzed on a FACSCAN (Becton Dickinson. Mountain View,
CA). The positive control is made by adding Phorbol Myristate Acetate (PMA) to the test system at a final concentration of 10-7 M.
In this example. CD62 was employed to measure the impact, if any, of irradiation alone on platelet activation. The antibody was stored in small aliquots (0.01 mg/ml) at -20°C prior to use. A mouse IgG control (0.05 mg/ml) (Becton Dickinson, Mountain View. CA #9040) 5X concentrated was employed. At time of use, this was diluted 1 :5 in HEPES buffer. The secondary antibody was goat Anti-Mouse IgG conjugated to FITC (TAGO, Burlingame, CA #3506). This was stored in small aliquots at -20°C. Phorbol Myristate Acetate (PMA) (Sigma. St. Louis, MO) was stored at -20°C. At time of use, this was dissolved in DMSO (working concentration was 1.62 X 10-5 M).
16%) Paraformaldehyde (PFA) (Sigma, St. Louis. MO) was prepared by adding 16 grams paraformaldehyde to 100 ml deionized water. This was heated to 70°C, whereupon 3 M NaOH was added dropwise until the solution was clear. The solution was cooled and the pH was adjusted to 7.4 with 1 N HCl. This was filtered and stored. A commercially available isotonic buffer was used: Hematall Isotonic Diluent (Fisher # CS 606-20).
For measuring platelet activation of platelet concentrates, a unit of human platelets was obtained from the Blood Bank of Alameda-Contra Costa Medical Association. 5 ml aliquots were drawn from the bag and received specified amounts of UVA irradiation, except for the control, which received no treatment other than being placed in a chamber for irradiation. Temperature was maintained at 25°C during irradiation by placing platelet concentrate in stoppered siliconized glass water-jacketed chambers attached to a circulating water bath. The irradiation device (Derma Control, Dolton, 111.; Model No. 1224-Special) was as described in Example 3. above.
Following irradiation, the platelets were stored for 5 days. At specific time points, aliquots were taken and processed.
Processing involved adding an aliquot (e.g., 5 microliters) of platelet concentrate to each microcentrifuge tube containing the antibody CD62, and appropriate reagents and this
was mixed very gently by vortex. The samples were incubated for 15 minutes at room temperature.
The Goat anti-Mouse IgG-FITC (diluted 1 :10 in HEPES buffer) was added (5 microliters) to each tube and the solution was mixed by gentle vortex. The samples were incubated for an additional 15 minutes at room temperature.
Isoton II was added (1 ml) to each tube and mixed gently with a polypropylene disposable pipet. 8% PFA in HEPES (150 microliters) was added to each diluted sample to final 1%). The platelets were analyzed on the FACSCAN. The results are shown in Table 1.
TABLE 1
Day 3 Day 5
PMA
Conditions Unactivated Unactivated PMA Aactivated Activated
Control 17 85 25 89
UV 5' 17 87 24 86
UV 10' 51 84 77 79
Activation is expressed as a percent. Clearly, irradiation for ten minutes (UV 10') resulted in a significant negative impact on stored platelets; the platelets were highly activated. By contrast, irradiation for five minutes (UV 5') resulted in no significant activation above the control which received no irradiation.
EXAMPLE 7
Given the results of Example 6, it is clear that either a shorter irradiation time or the use of filters is needed to avoid damage to cells by UV irradiation. In this example. CD62 is employed to measure the impact of irradiation in the presence of psoralen on platelet activation. Shorter irradiation times and wavelength filters are separately employed.
Shorter Irradiation Times. A unit of human platelets is again obtained from the Blood Bank of Alameda-Contra Costa Medical Association. 5 ml aliquots are drawn from the bag to receive five minutes (5') of UVA irradiation in the presence of 10 ug/ml 8-MOP. except for the control, which receives no treatment other than being placed in a chamber for irradiation.
Temperature is maintained at 25 °C during irradiation by placing platelet concentrate in stoppered siliconized glass water-jacketed chambers attached to a circulating water bath. The irradiation device (Derma Control. Dolton. 111.; Model No. 1224-Special) is as described in
Example 3. above. Following irradiation, the platelets are again stored for 5 days as in Example 6. At specific time points, aliquots are taken and assayed with the CD62 antibody and analyzed on the FACSCAN to show that, under these conditions, platelets can be decontaminated without damage to the cells and stored for five days prior to transfusion.
Wavelength Filters. An aqueous solution of Co(No3)2 is used in combination with NiSO4 to substantially remove the 365 nm component of the emission spectrum of the light source employed. The Co-Ni solution can be conveniently used in place of water as a coolant during the irradiation.
Following a ten minute irradiation with the filter, the platelets are stored and assayed with the CD62 antibody on the FACSCAN to show that, under these conditions, platelets can be decontaminated without damage to the cells and stored for five days prior to transfusion.
EXAMPLE 8
This example involves an assessment of the impact of mannitol on platelet function in synthetic media following irradiation. Three indicators of platelet viability and function were employed: 1) maintenance of pH; 2) platelet aggregation; and 3) ATP release.
To measure pH, a commercial device was used. A small amount of platelet concentrate was introduced into a CIBA-CORNING 238 pH/Blood Gas analyzer. Platelet aggregation and ATP release were measured with a CHRONOLOG Platelet Aggregometer with a Luminescence channel. The number of platelets in samples was controlled to be constant for every measurement. A Sysmex cell counter was used to measure platelet count in the platelet samples and AB plasma was used to adjust platelet counts to 300.000 per microliter of platelet concentrate.
For the procedure, all the samples were incubated in a cap plastic tube for 30 minutes at 37°C for activation. The optical channel is used for platelet aggregation measurement. A proportional amount of platelet concentrate and AB plasma were centrifuged at high speed (14,000 g) with a microfuge for 5 minutes in order to obtain platelet poor plasma. The aggregometer was warmed up to 37°C. The magnetic speed of the aggregometer was set at 600 /min and the Gain setting was set for the luminescence channel at 0.02.
To begin. 0.45 ml of platelet poor plasma was added along with 0.5 ml of saline into a glass cuvette and placed in the PPP channel. Then 0.45 ml of platelet concentrate and 0.50 ml of saline were added to a second glass cuvette (containing a small magnet) into the sample channel. After one minute. 30 ul of Lume enzyme (Chrono-log Corp., Havertown, PA) was added into the sample cuvette. After one minute, ADP and collagen reagents (10 ul) each were added to the sample cuvette. The final concentration of ADP was 10 μM and the final concentration of collagen was 5 μg/ml. Platelet aggregation and ATP release were recorded for about 8-10 minutes or until the maximum reading was reached.
An ATP standard was prepared in saline in four 10 ul aliquots (0.5, 1.0. 1.5 and 2.0 nmoles of ATP). For the ATP standard measurement, 0.45 ml of platelet concentrate and 0.5 ml of saline were added to a cuvette (containing a small magnet) into the sample channel. After one minute. 30 ul of Lume enzyme was added. After one minute. 10 ul of ATP standard was added. With the standard curve, the amount of ATP released from each sample was then determined. For measuring platelet pH, aggregation and ATP release in this experiment, a fresh unit of human platelet concentrate was obtained from Alameda-Contra Costa Blood Bank. As a control. 3 ml was removed and transferred to a Teflon™ minibag. The unit was then centrifuged at room temperature for 6 minutes at 4000 rpm and then transferred to a unit press. Using an attached transfer line, 30 ml of plasma was expressed from the unit into a sterile 50 ml centrifuge tube. The expressed plasma was then replaced with 30 ml of a commercially available synthetic media, plasmalyte-A (Baxter, Illinois).
The units were allowed to rest for one hour without shaking or mixing. Following a gentle kneading of the platelet pellet to resuspend the platelets, the bag was placed back on the rotator. The volume of platelet concentrate in the plasmalyte was measured to equal 42 ml (30 ml plasmalyte and 12 ml of plasma). 38 ml plasmalyte was added to the platelet suspension to give a 15% final plasma solution.
Fifty (50) ml of the 15% plasma solution was removed. To measure platelet function after irradiation, 125 ul of a 2 mg/ml 8-MOP solution in ethanol was added to the 50 ml aliquot. After mixing, a first 16 ml aliquot was removed from the 50 ml mixture and transferred to a sterile centrifuge tube. To this tube was added 64 ul of a 0.5 M mannitol solution in plasmalyte to get a final concentration of 2 mM. This platelet solution was transferred in 2.5 ml aliquots to each of 6 FL03 minibags.
A second 16 ml aliquot from the 50 ml mixture was transferred to a sterile centrifuge tube. In this case, 320 ul of a 0.5 M mannitol solution was added to get a final mannitol concentration of 10 mM. This platelet solution was transferred in 2.5 ml aliquots of this platelet concentrate to each of six (6) Teflon™ minibags. The remaining amount from the original 50 ml solution was divided into 6 minibags.
The minibags were then irradiated (0.5, 1.0, 2.5 , 5.0 or 10 minutes as needed) and stored. Platelet function was then followed over time. Figure 9 is a graph showing pH results. Figure 10 is a graph showing aggregation results, and Figure 11 is a graph showing ATP results. Figure 9. 10, and 11 indicate that extensive damage were obtained by one minute UVA irradiation on platelets resuspended in plasmalyte stored for 4 days. However, 2 and 10 mM mannitol protected platelets during a 2.5 minute UVA irradiation. Clearly, mannitol is helpful in synthetic media to preserve platelet function following irradiation.
EXAMPLE 9 This example involves an assessment of new synthetic media formulations as measured by the following in vitro platelet function assays: 1) maintenance of pH; 2) platelet aggregation ("Agg"); 3) ATP release; and 4) GMP140 expression. The assays for each of these tests have been described above.
Four formulations were prepared: S 2.19, S 2.22, S 3.0 and SAO. The composition of each of these is shown in Table 2 below:
TABLE 2*
S 2.19 S 2.22 S 3.0 S 4.0
Na gluconate 23 0 0 0
Na acetate 27 20 20 20 glucose 0 2 2 2 mannitol 30 20 0 20
KC1 5 4 4 4
NaCl 45 80 100 90
Na3 citrate 15 15 10 10
Na phosphate 20 20 20 20
MgCl2 0 2 2
Amounts in mM
One unit of human platelet rich plasma (PRP) was obtained from the Sacramento Blood Bank.
The unit was centrifuged at room temperature for 6 minutes at 4000 rpm and then transferred to a unit press. Using an attached transfer line, plasma was expressed from the unit, leaving approximately 9.4 mis of residual plasma.
The unit was allowed to rest for 1 hour, after which it was gently kneaded to resuspend the platelets. To 0.6 ml of the suspension, 2.4 ml of plasma was added back and the entire contents transferred to a Teflon™ minibag. The reconstituted unit was assayed for pH and other tests the next day. with the following results:
pH 7.19
GMP140 62%
Agg 58%
ATP 0.7
The remaining unit was then used to evaluate synthetic media for platelet storage with and without photodecontamination. Aliquots (0.8 ml) from the unit were added to each formulation (3.2 mis) in tubes. 3 mis of each mixture was transferred to a Teflon™ minibag (final plasma concentration of 20%).
Five days later, platelet function was assessed using the battery of tests described above. The results for each of the synthetic media formulations are shown in Table 3 below.
TABLE 3 no light light
S 2.19 S 2.22 S 2.19 S 2.22 pH 6.86 6.82 6.83 6.60
GMP140 87% 74% 90%) 80%
Agg 30 48 16 31
It appeared that the synthetic media containing 2 mM glucose (i.e.. S 2.22) maintained platelet function, as measured by GMP140 and Aggregation, better than the synthetic media that did not contain glucose (i.e., S 2.19).
To confirm the above finding, experiments were repeated ("n" being the number of replicate experiments) with these formulations as well as additional glucose-free formations (3.0 and 4.0). Platelet function was evaluated both before and after storage, and in conjunction with photodecontamination. A summary of the results is provided in Tables 4, 5 and 6 below.
TABLE 4*
Plasma S 2.22 S 3.0 S 4.0 S 2.19 n=17 n=22 n=4 n=4 n=23 pH 7.31 7.14 7.12 7.13 7.04
Agg 82 83 76 78 81
ATP 0.8 0.9 1.0 1.0 1.5
GMP-140 52 49 46 45 68
No UVA; Day 1 of Storage
TABLE 5*
Plasma S 2.22 S 3.0 S 4.0 S 2.19 n=18 n=20 n=4 n=4 n=23 pH 7.03 6.92 6.93 6.93 6.96
Agg 75 70 67 70 64
ATP 0.6 0.5 0.5 0.5 0.7
GMP-140 61 63 63 64 74
No UVA: Day 5 of Storage
TABLE 6*
S 2.22 S 3.0 S 4.0 S 2.19 n=20 n=4 n=4 n=22
PH 6.80 6.78 6.79 6.95
Agg 59 54 54 58
ATP 0.4 0.3 0.4 0.6
GMP-140 73 76 76 83
3 Joules UVA; Day 5 of Storage
EXAMPLE 10
Figure 12 shows an embodiment wherein platelets are diluted with synthetic media by the method of the present invention. Figure 12A schematically shows the standard blood product separation approach used presently in blood banks. Three bags are integrated by flexible tubing to create a blood transfer set (200) (e.g., commercially available from Baxter, Deerfield, 111.). After blood is drawn into the first bag (201), the entire set is processed by centrifugation (e.g., Sorvall™ swing bucket centrifuge, Dupont), resulting in packed red cells and platelet rich plasma in the first bag (201). The plasma is expressed off of the first bag (201) (e.g., using a Fenwall™ device for plasma expression), through the tubing and into the second bag (202). The first bag (201) is then detached and the two bag set is centrifuged to create platelet concentrate and platelet-poor plasma; the latter is expressed off of the second bag (202) into the third bag (203).
Figure 12B schematically shows an embodiment of the present invention by which synthetic media is introduced to platelet concentrate prepared as in Figure 12A. A two bag
set (300) is sterile docked with the platelet concentrate bag (202) (indicated as "P.C."). Sterile docking is well-known to the art. See e.g., U.S. Patent No. 4,412,835 to D.W.C. Spencer, hereby incorporated by reference. See also U.S. Patents Nos. 4,157,723 and 4.265.280. hereby incorporated by reference. Sterile docking devices are commercially available (e.g., Terumo. Japan).
One of the bags (301) of the two bag set (300) contains a synthetic media formulation of the present invention (indicated as "STERILYTE"). In the second step shown in Figure 12B. the platelet concentrate is mixed with the synthetic media by transferring the platelet concentrate to the synthetic media bag (301). Figure 12C schematically shows one embodiment of the decontamination approach of the present invention applied specifically to platelet concentrate diluted with synthetic media as in Figure 12B. In this embodiment, platelets have been transferred to a synthetic media bag (301) containing a nucleic acid binding compound. This bag (301), which has UV light transmission properties and other characteristics suited for the present invention, is then placed in a device (such as that described in Example 1 , above) and illuminated.
Following phototreatment, the platelets are transferred from the synthetic media bag (301) into the storage bag (302) of the two bag set (300). The storage bag can be a commercially available storage bag (e.g., CLX bag from Cutter).
From the above, it should be evident that the present invention provides synthetic media formulations for use with blood preparations intended for storage and in vivo use. The formulations include synthetic media formulations to be employed in conjunction with the photodecontamination of platelets.
Claims
1. A method of inactivating microorganisms in platelet preparations for subsequent transfusion, comprising: a) providing, in any order; i) psoralen, ii) photoactivation means, and iii) a platelet preparation suspected of being contaminated with microorganisms, comprising platelets and plasma; b) adding said psoralen to said platelet preparation to create a solution of psoralen at a concentration; c) treating said solution with said photoactivation means so as to create a treated platelet preparation wherein said microorganisms are inactivated and wherein at least a portion of said psoralen concentration is free in said solution; and d) removing some of said free psoralen in said treated platelet preparation.
2. The method of Claim 1, further comprising the step, after step d), of storing said mixture at approximately room temperature prior to transfusion.
3. The method of Claim 1, wherein said activating means comprises a photoactivation device capable of emitting a given intensity of a spectrum of electromagnetic radiation comprising wavelengths between 320 nm and 380 nm.
4. The method of Claim 3, wherein said intensity is less than 25 mW/cnr.
5. The method of Claim 4, wherein said mixture is exposed to said intensity for between one and ten minutes.
6. The method of Claim 1, wherein said removing of said free psoralen comprises contacting said platelets with a psoralen-binding polymer.
7. The method of Claim 6, wherein said contacting comprises transferring said platelets to a blood bag comprised of psoralen-binding polymer.
8. A method of inactivating microorganisms in platelet preparation for transfusions, comprising: a) providing, in any order; i) psoralen, ii) synthetic media, iii) photoactivation means, and iv) a platelet preparation suspected of being contaminated with microorganisms, comprising platelets and plasma; b) removing a portion of said plasma from said preparation and adding said synthetic media containing said psoralen to said platelets such that said platelets are suspended in mixture having a residual plasma concentration; c) treating said mixture with said photoactivation means so as to create a treated platelet solution wherein said microorganisms are inactivated and wherein at least a portion of said psoralen concentration is free in said solution; and d) removing substantially all of said free psoralen in said treated platelet solution.
9. The method of Claim 8, further comprising the step, after step d), of storing said mixture at approximately room temperature prior to transfusion.
10. The method of Claim 8, wherein said activating means comprises a photoactivation device capable of emitting a given intensity of a spectrum of electromagnetic radiation comprising wavelengths between 320 nm and 380 nm.
11. The method of Claim 10, wherein said intensity is less than 25 mW/cml
12. The method of Claim 11, wherein said mixture is exposed to said intensity for between one and ten minutes.
13. The method of Claim 8, wherein said removing of said free psoralen comprises contacting said treated solution with a psoralen-binding polymer.
14. The method of Claim 13, wherein said contacting comprises transferring said treated solution to a blood bag comprised of psoralen-binding polymer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60255/96A AU6025596A (en) | 1995-06-07 | 1996-05-29 | Psoralen-binding polymers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/480,013 US5709991A (en) | 1992-03-02 | 1995-06-07 | Proralen inactivation of microorganisms and psoralen removal |
US08/480,013 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996039815A1 true WO1996039815A1 (en) | 1996-12-19 |
Family
ID=23906322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/007896 WO1996039815A1 (en) | 1995-06-07 | 1996-05-29 | Psoralen-binding polymers |
Country Status (3)
Country | Link |
---|---|
US (1) | US5709991A (en) |
AU (1) | AU6025596A (en) |
WO (1) | WO1996039815A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016014854A1 (en) | 2014-07-23 | 2016-01-28 | Cerus Corporation | Methods for preparing platelet products |
WO2016057965A1 (en) | 2014-10-10 | 2016-04-14 | Cerus Corporation | Compositions and methods for treating viral hemorrhagic fever |
WO2016210374A1 (en) | 2015-06-26 | 2016-12-29 | Cerus Corporation | Cryoprecipitate compositions and methods of preparation thereof |
WO2017070619A1 (en) | 2015-10-23 | 2017-04-27 | Cerus Corporation | Plasma compositions and methods of use thereof |
WO2017120545A2 (en) | 2016-01-07 | 2017-07-13 | Cerus Corporation | Systems and methods for preparation of platelets |
WO2018161020A1 (en) | 2017-03-03 | 2018-09-07 | Cerus Corporation | Kits and methods for preparing pathogen-inactivated platelet compositions |
WO2019060610A1 (en) | 2017-09-20 | 2019-03-28 | Cerus Corporation | Compositions and methods for pathogen inactivation of platelets |
WO2019133929A1 (en) | 2017-12-29 | 2019-07-04 | Cerus Corporation | Systems and methods for treating biological fluids |
US11883544B2 (en) | 2019-06-28 | 2024-01-30 | Cerus Corporation | System and methods for implementing a biological fluid treatment device |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618662A (en) * | 1992-03-02 | 1997-04-08 | Cerus Corporation | Intravenous administration of psoralen |
AU4107396A (en) * | 1992-03-02 | 1996-06-06 | Cerus Corporation | Synthetic media for blood components |
US5556993A (en) | 1993-06-28 | 1996-09-17 | Steritech, Inc. | Compounds for the photodecontamination of pathogens in blood |
US6420570B1 (en) | 1993-06-28 | 2002-07-16 | Cerus Corporation | Psoralen compounds |
US5399719A (en) | 1993-06-28 | 1995-03-21 | Steritech, Inc. | Compounds for the photodecontamination of pathogens in blood |
US6984526B2 (en) * | 1995-02-08 | 2006-01-10 | University Of South Florida | Spectrophotometric method for determining the viability of a sample containing platelets |
AU714882B2 (en) * | 1996-04-09 | 2000-01-13 | Therakos, Inc. | Method for removal of psoralens from biological fluids |
US5922278A (en) * | 1996-11-19 | 1999-07-13 | Baxter International Inc. | Method and apparatus for inactivating contaminants in biological fluid |
US6190609B1 (en) | 1996-11-19 | 2001-02-20 | Baxter International Inc. | Methods and apparatus for inactivating contaminants in biological fluid |
DE69819360T2 (en) * | 1997-11-20 | 2004-08-19 | Cerus Corp., Concord | NEW PSORAL FOR INACTIVATION OF PATHOGENES |
US20030215784A1 (en) * | 1998-07-21 | 2003-11-20 | Dumont Larry Joe | Method and apparatus for inactivation of biological contaminants using photosensitizers |
US7049110B2 (en) * | 1998-07-21 | 2006-05-23 | Gambro, Inc. | Inactivation of West Nile virus and malaria using photosensitizers |
US6258577B1 (en) | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
US7498156B2 (en) * | 1998-07-21 | 2009-03-03 | Caridianbct Biotechnologies, Llc | Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components |
US6277337B1 (en) | 1998-07-21 | 2001-08-21 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
US20070099170A1 (en) * | 1998-07-21 | 2007-05-03 | Navigant Biotechnologies, Inc. | Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate |
US7445756B2 (en) * | 1999-06-03 | 2008-11-04 | Fenwal, Inc. | Fluid processing sets and organizers for the same |
US7068361B2 (en) * | 1999-06-03 | 2006-06-27 | Baxter International | Apparatus, systems and methods for processing and treating a biological fluid with light |
US7025877B1 (en) | 1999-06-03 | 2006-04-11 | Baxter International Inc. | Processing set for processing and treating a biological fluid |
US6565802B1 (en) | 1999-06-03 | 2003-05-20 | Baxter International Inc. | Apparatus, systems and methods for processing and treating a biological fluid with light |
US7220747B2 (en) * | 1999-07-20 | 2007-05-22 | Gambro, Inc. | Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer |
US6268120B1 (en) | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
SE0000866L (en) * | 2000-03-16 | 2001-09-17 | Peter Unger Med P U Med Konsul | Method and apparatus for the treatment of biological material |
TW590780B (en) * | 2000-06-02 | 2004-06-11 | Gambro Inc | Additive solutions containing riboflavin |
US7648699B2 (en) * | 2000-06-02 | 2010-01-19 | Caridianbct Biotechnologies, Llc | Preventing transfusion related complications in a recipient of a blood transfusion |
US7985588B2 (en) * | 2000-06-02 | 2011-07-26 | Caridianbct Biotechnologies, Llc | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light |
US6843961B2 (en) * | 2000-06-15 | 2005-01-18 | Gambro, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
US7381976B2 (en) | 2001-03-13 | 2008-06-03 | Triton Thalassic Technologies, Inc. | Monochromatic fluid treatment systems |
US20030228564A1 (en) * | 2001-05-30 | 2003-12-11 | Edrich Richard Alan | Nitric oxide in a pathogen inactivation process |
WO2003049801A1 (en) * | 2001-12-12 | 2003-06-19 | Lewandowski Leon J | Photophoretic auto immune stimulation |
WO2003066110A1 (en) * | 2002-02-01 | 2003-08-14 | Gambro, Inc. | Pathogen reduction solution for platelets containing an endogenous photosensitizer and a glycolysis inhibitor. |
US20040029097A1 (en) * | 2002-04-16 | 2004-02-12 | Gambro, Inc. | Addition of glycolysis inhibitor to a pathogen reduction and storage solution |
CA2482021C (en) * | 2002-04-24 | 2007-06-19 | Gambro, Inc. | Removal of adenine during a process of pathogen reducing blood and blood components |
WO2003090794A1 (en) * | 2002-04-26 | 2003-11-06 | Gambro, Inc. | Solution containing platelet activation inhibitors for pathogen reducing and storing blood platelets |
US20090023130A1 (en) * | 2003-02-28 | 2009-01-22 | Caridianbct Biotechnologies, Llc | Prevention of Transfusion Related Acute Lung Injury Using Riboflavin and Light |
US7306716B2 (en) * | 2004-06-16 | 2007-12-11 | Access Business Group International Llc | Water treatment system |
US8709445B2 (en) * | 2007-07-31 | 2014-04-29 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Vaccination with killed but metabolically active (KBMA) protozoans with toll-like receptor agonists |
AU2008282232A1 (en) * | 2007-08-01 | 2009-02-05 | Terumo Bct Biotechnologies, Llc. | Pathogen inactivation of whole blood |
WO2010039994A2 (en) * | 2008-10-01 | 2010-04-08 | Caridianbct, Inc. | Platelet additive solution for leukoreducing white blood cells in apheresed platelets |
US20140127077A1 (en) | 2012-11-05 | 2014-05-08 | Gail Rock | Device and method for sterilization of instruments and surfaces |
US20230201418A1 (en) * | 2021-12-28 | 2023-06-29 | Shanghai Qisheng Biological Preparation Co., Ltd. | Soft tissue augmentation using injectable, neutral ph soluble collagen-glycosaminoglycan compositions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288605A (en) * | 1992-03-02 | 1994-02-22 | Steritech, Inc. | Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4124598A (en) * | 1976-10-20 | 1978-11-07 | Hoffmann-La Roche Inc. | Psoralens |
US4196281A (en) * | 1976-10-20 | 1980-04-01 | Regents Of The University Of California | Psoralens |
US4169204A (en) * | 1976-10-20 | 1979-09-25 | Regents Of The University Of California | Psoralens |
US4157723A (en) * | 1977-10-19 | 1979-06-12 | Baxter Travenol Laboratories, Inc. | Method of forming a connection between two sealed conduits using radiant energy |
US4265280A (en) * | 1979-01-23 | 1981-05-05 | Baxter Travenol Laboratories, Inc. | Connector member for sealed conduits |
US4390619A (en) * | 1981-09-28 | 1983-06-28 | James Clifford Haight | Leukocyte or platelet storage using ion-exchange resins |
US4412835A (en) * | 1982-07-06 | 1983-11-01 | E. I. Du Pont De Nemours & Company | Sterile docking process, apparatus and system |
CA1216518A (en) * | 1982-11-01 | 1987-01-13 | Gail A. Rock | Plasma-free medium for platelet storage |
US4684521A (en) * | 1982-12-08 | 1987-08-04 | Frederic A. Bourke, Jr. | Method and system for externally treating the blood |
US4748120A (en) * | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
US4727027A (en) * | 1983-05-02 | 1988-02-23 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
US4992363A (en) * | 1983-11-09 | 1991-02-12 | Thomas Jefferson University | Method for preparing glucose free media for storing blood platelets |
US4828976A (en) * | 1983-12-29 | 1989-05-09 | Thomas Jefferson University | Glucose free media for storing blood platelets |
US4693981A (en) * | 1983-12-20 | 1987-09-15 | Advanced Genetics Research Institute | Preparation of inactivated viral vaccines |
US4704352A (en) * | 1985-06-25 | 1987-11-03 | Baxter Travenol Laboratories, Inc. | L-ascorbate-2-phosphate salts in blood cell storage |
US4695460A (en) * | 1986-03-19 | 1987-09-22 | American Red Cross | Synthetic, plasma-free, transfusible platelet storage medium |
US4925665A (en) * | 1989-06-22 | 1990-05-15 | Thomas Jefferson University | Glucose free primary anticoagulant for blood containing citrate ions |
AU4677993A (en) * | 1992-08-07 | 1994-03-03 | Steritech, Inc. | Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen |
US5459030A (en) * | 1992-03-02 | 1995-10-17 | Steritech, Inc. | Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen |
-
1995
- 1995-06-07 US US08/480,013 patent/US5709991A/en not_active Expired - Fee Related
-
1996
- 1996-05-29 WO PCT/US1996/007896 patent/WO1996039815A1/en active Application Filing
- 1996-05-29 AU AU60255/96A patent/AU6025596A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288605A (en) * | 1992-03-02 | 1994-02-22 | Steritech, Inc. | Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen |
Non-Patent Citations (1)
Title |
---|
WALTER REED RESEARCH REPORT WRAIR-53-55, November 1955, HEINMETS et al., "Inactivation of Viruses in Plasma by Photosensitized Oxidation", pages 1-16. * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10842818B2 (en) | 2014-07-23 | 2020-11-24 | Cerus Corporation | Methods for preparing platelet products |
WO2016014854A1 (en) | 2014-07-23 | 2016-01-28 | Cerus Corporation | Methods for preparing platelet products |
WO2016057965A1 (en) | 2014-10-10 | 2016-04-14 | Cerus Corporation | Compositions and methods for treating viral hemorrhagic fever |
WO2016210374A1 (en) | 2015-06-26 | 2016-12-29 | Cerus Corporation | Cryoprecipitate compositions and methods of preparation thereof |
US11096963B2 (en) | 2015-06-26 | 2021-08-24 | Cerus Corporation | Cryoprecipitate compositions and methods of preparation thereof |
WO2017070619A1 (en) | 2015-10-23 | 2017-04-27 | Cerus Corporation | Plasma compositions and methods of use thereof |
US10799533B2 (en) | 2015-10-23 | 2020-10-13 | Cerus Corporation | Plasma compositions and methods of use thereof |
WO2017120545A2 (en) | 2016-01-07 | 2017-07-13 | Cerus Corporation | Systems and methods for preparation of platelets |
WO2018161020A1 (en) | 2017-03-03 | 2018-09-07 | Cerus Corporation | Kits and methods for preparing pathogen-inactivated platelet compositions |
US11235090B2 (en) | 2017-03-03 | 2022-02-01 | Cerus Corporation | Kits and methods for preparing pathogen-inactivated platelet compositions |
WO2019060610A1 (en) | 2017-09-20 | 2019-03-28 | Cerus Corporation | Compositions and methods for pathogen inactivation of platelets |
WO2019133929A1 (en) | 2017-12-29 | 2019-07-04 | Cerus Corporation | Systems and methods for treating biological fluids |
US11554185B2 (en) | 2017-12-29 | 2023-01-17 | Cerus Corporation | Systems and methods for treating biological fluids |
US11883544B2 (en) | 2019-06-28 | 2024-01-30 | Cerus Corporation | System and methods for implementing a biological fluid treatment device |
Also Published As
Publication number | Publication date |
---|---|
US5709991A (en) | 1998-01-20 |
AU6025596A (en) | 1996-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5459030A (en) | Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen | |
US5709991A (en) | Proralen inactivation of microorganisms and psoralen removal | |
US5965349A (en) | Methods of photodecontamination using synthetic media | |
US6251580B1 (en) | Synthetic media for blood components | |
US5482828A (en) | Synthetic media compositions and methods for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen | |
US5288605A (en) | Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen | |
US6586749B2 (en) | Device and method for photoactivation | |
EP0727938B1 (en) | Device and method for photoactivation | |
AU772088B2 (en) | Device and method for photoactivation | |
AU739806B2 (en) | Device and method for photoactivation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |